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Abstract 
7,8-Diaminopelargonic acid synthase (BioA) of Mycobacterium tuberculosis (Mtb) is a 
recently validated target for therapeutic intervention in the treatment of tuberculosis (TB). 
We herein report our fragment based inhibitor design of Mtb BioA. Using differential 
scanning fluorimetry (DSF) fragment screening, the Maybridge Ro3 library of 1000 
molecules was screened. Twenty-one compounds giving rise to Tm shifts exceeding  
±2°C were then investigated in crystallographic experiments. Six fragments have been 
co-crystallized with BioA to characterize binding. Each compound has a unique binding 
mode, and subtle variations in ligand binding site geometry are induced upon binding of 
different fragment molecules. Binding affinities of the fragments were characterized via 
isothermal titration calorimetry (ITC). A fragment extension strategy was used to 
rationally optimize these fragment hits. A commerce based SAR was used and identified 
50 compounds containing the core of one of the fragments. These compounds were 
further screened virtually and experimently by DSF. Four optimized BioA ligands from 
fragment optimization were validated by X-ray crystallography, including a potent aryl 
hydrazine inhibitor of BioA that reversibly modifies the pyridoxal-5ʹ′-phosphate (PLP) 
cofactor. Binding affinities of these ligands have been characterized by ITC or kinetic 
assay. The six fragment complex structures were also used for optimization of HTS lead 
compounds. Six HTS lead compounds were co-crystallized with BioA at high resolution. 
Design of optimized compounds was by overlapping the fragments and HTS lead 
binding conformations in the BioA active site. Molecules predicted to have better potency 
were proposed. Two N-aryl piperazine inhibitors of BioA from HTS optimization were 
characterized using X-ray crystallography and ITC. One inhibitor that combines features 
of one HTS lead and one fragment was confirmed with improved binding affinity by ITC.
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Chapter I: Introduction 
Acknowledgement: Figure 1.3 in this chapter is excerpted from previously published 
work [Dai, R. et al, 2014. "Inhibition of Mycobacterium tuberculosis Transaminase BioA 
by Aryl Hydrazines and Hydrazides ". ChemBioChem. 15(4):575-586]. 
 
1.1. Significance of novel anti-tubercular drugs 
 
1.1.1. Current Progress on TB treatment 
Tuberculosis (TB) is a major global health issue that causes over 1.8 million deaths 
annually1. Mycobacterium tuberculosis (Mtb) is the major pathogen causing TB in 
humans.  Mtb first infects macrophages in the lungs. If the immune system fails to 
eradicate the bacilli in macrophages, Mtb can further spread to secondary infection sites 
in an uncontrolled pattern and lead to active clinical disease2. The Mtb infection can also 
be latent, in which case adaptive immunity is able to restrain the bacilli growth by 
controlling its replication for years, even decades, until a waning of immunity allows 
reactivation of the disease3. Based on the global incidence of a positive response in the 
tuberculin skin test, about 2 billion people have latent infection of Mtb. 10% of these 2 
billion people will develop an active infection in their lifetime1. Because a compromised 
immune system can struggle to keep latent infections in check, HIV infection significantly 
increases the risk of conversion to active TB, and TB has become the major cause of 
death in people with AIDS4. 
 
The discovery of effective chemotherapies for TB began in the 1940s, and dozens of first 
and second line drugs have been developed since then. Let us review several 
landmarks in the history of TB medical development. 
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The first chemotherapies Streptomycin (STR) and para-aminosalicyclic acid (PAS) were 
discovered and used in the 1940s5 (Figure 1.1a). STR belongs to the aminoglycoside 
antibiotic family. It is a protein synthesis inhibitor, which binds to the 30S subunit of the 
bacterial ribosome and causes codon misreading in bacterial protein synthesis.  PAS 
was used as anti-mycobacterial for more then 60 years even though its mechanism of 
action remains only partially known. Recent studies have shown that PAS is a prodrug 
targeting dihydrofolate reductase (DHFR); it needs to be activated via the Mtb folate 
biosynthesis pathway to acquire DHFR inhibition activity6,7.  
 
In the 1950s, isoniazid (INH) was discovered and the triple drug combination (STR, PAS, 
INH) was found to be superior to other therapies (Figure 1.1 b1). Isoniazid is a prodrug 
activated by Mtb catalase-peroxidase (KatG) to form an isonicotinic acyl-NADH complex. 
This complex can bind to the enoyl-acyl carrier protein reductase (InhA) and block the 
binding of natural substrates. In this way, isoniazid inhibits the synthesis of mycolic acid, 
which is a crucial precursor for Mtb cell wall synthesis. In 1952, a triple therapy 
(streptomycin, para-aminosalicylic acid and isoniazid) resulting in an “assured cure” was 
established with a treatment duration of 18 months5. 
 
In the 1970s, the discovery of rifampicin (RIF) (Figure 1.1 b2) brought about a revolution 
in TB therapy, because it allowed the length of therapy to be significantly shortened 
(from 18 months to 9 months). Later in the 1980s, a 6-month short course chemotherapy 
was introduced for drug-susceptible TB that resulted in a cure rate exceeding 95%8. In 
this therapy, a four-drug regimen composed of RIF, INH, Ethambutol (EMB) (Figure 1.1 
b3) and pyrazinamide (PZA) (Figure 1.1 b4) was used in the first 2 months as the 
intensive phase of therapy; then RIF and INH was used for an additional 4 months as a 
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continuation9. RIF, INH, EMB and PZA were subsequently named as first line anti-TB 
drugs. RIF is a DNA-dependent RNA polymerase inhibitor that inhibits Mtb RNA 
synthesis9. EMB disrupts Mtb cell wall synthesis by inhibiting an enzyme arabinosyl 
transferase, which is responsible in cell wall formation10. PZA is a prodrug; it first diffuses 
into Mtb and then it can be converted into the active metabolite pyrazinoic acid by 
pyrazinamidase; then the active form can inhibit Mtb fatty acid synthesis11. 
 
Beginning in the 1990s, strains of Mtb that are increasingly resistant to available drugs 
began to arise as formidable new  challenges to human health. The term MultiDrug-
Resistant TB (MDR-TB) is specifically used to refer to clinical isolates that are resistant 
to both INH and RIF, the two most important first line anti-TB drugs. To treat MDR-TB or 
TB with even higher degrees of resistance, WHO has recommended second line anti-TB 
drugs (WHO groups 2, 3, and 4) 8. When treatment employing combinations of the four 
first line anti-TB drugs encounter resistance or intolerance issues, second line antibiotics 
should be used.  These second line drugs include amikacin, kanamycin, capreomycin, 
fluoroquinolones, ethionamide, prothionamide, cycloserine, and PAS. These antibiotics 
are categorized as the second line drugs because they possess unconfirmed clinical 
efficacy, have substantially greater adverse effects, and in some cases unfavorable 
pharmacokinetic profiles. When fewer than 5 effective drugs from the first line and 
second line can be selected for the resistant TB, some third line antibiotics from a non-
WHO approved list (macrolides such as clarithromycin, augmentin, meropenem and 
clavulanate, clofazimine, linezolid, thioacetazone, and thioridazine) are allowed to be 
prescribed. The efficacy of third line anti-TB drugs are yet to be proven. 
 
Because of the extensive use of inactive second and third line antibiotics in the 
treatment of MDR-TB, there is a rise in the occurrence of extensively drug-resistant 
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tuberculosis (XDR-TB). The XDR-TB is resistant to some key components in the second 
and third line drugs, including at least one fluoroquinolone and one of the injectable 
antibiotics (i.e. streptomycin, amikacin, capreomycin)12. The cure rate for the XDR-TB 
can be as low as 30%13. Even more horrifying, there are reports of totally drug-resistant 
TB (TDR-TB) for which there is no effective chemotherapy. 
 
Bedaquiline is the first new agent approved for the treatment of Mtb since Rifampin in 
1970 (Figure 1.1 c1). In 2012, the U.S Food and Drug Administration (FDA) approved 
Bedaquiline for use in TB treatment, but only for use in cases of severe MDR-TB or 
XDR-TB, which lack other treatment options. Betaquiline acts as a Mtb ATP synthase 
inhibitor, and is the first-in-class to employ this novel mechanism. There remains some 
controversy regarding the current clinical trial of Bedaquiline. Its manufacturer Johnson 
& Johnson (J&J) was able to get accelerated approval of the drug. This fast-track 
approval is only for cases of MDR and XDR tuberculosis. For this case, FDA’s approval 
was based on the outcome of the sputum cultures rather than the patients’ death rate. 
As clinical cases have accumulated, it was been shown that Bedaquiline usage 
increased the death rate by 5 times comparing to the control group. One significant 
reason for the increased death rate may be failure of treatment of the bacteria due to 
lack of antibacterial efficacy; there are also toxicity issues still being investigated.     
 
1.1.2. Importance and challenges of TB drug development 
 
TB drug development has regained scientists’ attention; however, compared to the rapid 
development of resistance, the drug development progress is unfortunately very slow. 
There are at least three goals when developing new anti-tubercular drugs. 
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First, the standard treatment for the current drug sensitive TB needs to be simplified and 
shortened. The conventional “short course” regimen requires 6-month usage of RIF. 
Studies have shown that premature discontinuation or poor adherence in RIF usage can 
increase the rate of relapse and facilitate development of resistance in the disease14. 
The World Health Organization (WHO) has developed a “DOTS” (directly observed 
treatment, short-course) strategy to control the spread and resistance development of 
TB. “DOTS” has 5 main components: government commitment, smear positive 
detection, observed treatment, ensured drug supply and standardized reporting 
systems15. Although DOTS is considered the most effective and economical TB control 
strategy, it is a very expensive program that is difficult to enforce, as it requires some 
methods of treatment observation (i.e. hospitalizing the patients) to ensure the proper 
drug usage. Especially in some developing countries, patients often discontinue their 
therapy when their symptoms are alleviated. Thus, although DOTS and the short-course 
treatment being recommended, Multi-Drug Resistance problems still emerged due to 
poor compliance or improper treatments. Thus, the current situation calls for the 
development of more effective chemotherapies that can shorten and simplify the 
regimen and lower the treatment cost. 
 
Second, drugs that act on new targets or through new mechanisms of action are needed 
for resistant TB. Since the 1990s, MDR-TB and XDR-TB has rapidly emerged, first within 
hospitals, later transmitted into the community. To treat MDR-TB and control the spread 
of resistant TB, the WHO has extended the “DOTS” strategy to “DOTS-plus”. “DOTS-
plus” allows use of agents from a list of second line anti-TB drugs; even though the 
efficacy of these second line drugs has yet to be confirmed. So far for MDR-TB, the cure 
rate is 80%. For XDR-TB, however, there is not a standard strategy. Treatment often 
involves using of a large variety of third line antibiotics that may not be effective at all, 
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and the cure rate is very low (30%). It is not hard to foresee that the current inadequate 
treatment for MDR-TB and XDR-TB can further stimulate the rate of TB resistance 
development. For this reason, efforts on the development of chemotherapies working on 
new mechanisms are badly needed. 
 
Third, effective cures for latent TB infection are wanted. As reported by the WHO, over 2 
billion people have latent TB infection1, and 10% of these people will develop active TB 
infection in their lifetime. The TB reactivation rate has significantly increased with 
increased cases of HIV infections, and TB infection has also become the greatest death 
risk for HIV patients. The high death rate for the TB co-infected HIV patients is due to 
lack of effective treatment. The standard 6 month regimen is problematic because, the 
most important chemotherapy RIF cannot be used by HIV patients undergoing 
antiretroviral therapy. RIF is a cytochrome P450 (CYP) 3A4 inducing agent; it has 
significant drug-drug interactions with many anti-HIV drugs16.  There are efforts to 
identify substitutes for RIF that are compatible with anti-HIV drugs17. An alternative 
perspective to solve this issue is to develop cures for latent TB infection. So far there is 
no way to kill dormant bacteria that lie hidden during latent infection. Available Mtb drugs 
only attack proliferating Mtb, and do not kill dormant bacteria. Developing antitubercular 
drugs targeting dormant Mtb infection will help the 2 billion people with latent TB 
infection. 
 
1.2. BioA as an anti-Mtb target 
 
1.2.1. Mtb Targets of The Biotin Biosynthesis Pathway 
As we have pointed out in 1.1.2, drugs that act through novel mechanisms on new 
targets will be vital as chemotherapeutic tools addressing current resistance problems. 
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For this reason, extensive work is being done in attempt to identify novel TB druggable 
targets. Many reported target-based screening methods are problematic and result in 
low success rates in identification of compounds that enter further drug development; i.e. 
the hits from the initial target-based high throughput screening (HTS) assays usually turn 
out not being validated in the later cell based assays and animal models18. For example, 
GlaxoSmithKline performed a retrospective assessment of over 70 screening campaigns 
in which only 5 hit compounds were advanced for further drug development19. To identify 
new targets that can be inhibited in vivo, whole cell screenings were conducted where 
targets are paired with lead compounds with whole cell activity. In 2013, Sacchittini et al. 
identified TB drug targets using a whole cell based screening assay18. Using this 
screening method, they not only identified new TB drug targets, but also identified lead 
compounds with whole cell activity that could be paired with the identified targets. These 
targets include aspartyl-tRNA synthetase, polyketide synthase Pks13, membrane 
transporter MmpL3, and ESX-3 type VII secretion system EccB3. The whole cell 
screening method gives rise to a higher rate of lead identification. An important lesson 
from these different screening approaches is that working on a validated target is crucial 
for novel anti-TB drug development.   
 
To identify all molecular mechanisms that are crucial for the survival of Mtb during 
infection, Sassetti et al. mutated every gene not known to be essential of Mtb and 
discovered that every gene in the biotin synthetic pathway is essential for Mtb infection 
in a mouse model (except bioD for which the data is not available)20. This finding is 
meaningful for anti-TB drug development, because unlike bacteria or plants, mammalian 
hosts do not have enzymes for biotin cofactor synthesis21. Since no homologues of 
these enzymes exist in humans, they may be safely targeted within bacteria in a human 
host. 
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Four enzymes are involved in the biotin biosynthetic pathway (Figure 1.2). In the first 
step, KAPA synthase (BioF) catalyzes the decarboxylative condensation of pimeloyl-
CoA with L-alanine to form 7-keto-8-aminopelargonic acid (KAPA). In the second step, 
the PLP-dependent DAPA synthase (BioA) catalyzes the transamination reaction to 
produce 7,8-diaminopelargonic acid (DAPA) from KAPA; in this reaction, S-
adenosylmethionine (SAM) is used as the amino donor. Dethiobiotin synthetase (BioD) 
catalyzes the third step, the carboxylation of DAPA to produce the imidazolidin-2-one 
ring of dethiobiotin (DTB). Finally, biotin synthase (BioB), an iron−sulfur cluster enzyme, 
converts DTB into biotin by catalyzing the C-H activation and insertion of sulfur into DTB 
in the fourth step of biotin synthesis. 
 
Among the four enzymes in the Mtb biotin biosynthesis pathway, BioA is the most well 
studied. BioA and BioD are the only two proteins in this pathway that have been 
structurally characterized21. Sae Woong Park et al. in 2011 published their study that 
further confirmed that the expression of BioA protein is essential for the acute and 
chronic infection of TB in a murine model22. In their experiment, a knockout and a 
knockdown of Mtb BioA gene models were built. The experimental results showed that 
without Mtb BioA expression, Mtb cells are unable to survive in vivo or in mice without a 
supplemental biotin source. From these experimental results, BioA is validated to be a 
novel effective target for both active and latent TB infection. 
 
BioA (also known as DAPA synthase) is a Class I aminotransferase responsible for the 
conversion of 7-keto-8-aminopelargonic acid (KAPA) to 7,8-diaminopelargonic acid 
(DAPA) employing S-adenosyl methionine (SAM) as the amino donor. Catalysis is 
facilitated via a ping-pong bi-bi mechanism using PLP as a co-factor23 that cycles 
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between the reduced pyridoxamine (PMP) and oxidized (PLP) states (Figure 1.3). First, 
SAM reacts with the internal aldimine of PLP and Lys283 to donate an amino group to 
the PLP, forming pyridoxamine phosphate (PMP). KAPA then reacts with the PMP-
bound form of BioA, receiving the amino group to form the product DAPA. With this last 
step, BioA returns to its PLP bound holo form. 
 
Generally, transaminases can use many endogenous amino acids as amino donors, but 
BioA has an unusual preference for SAM, which more often serves as a methyl donor24. 
SAM is structurally very different from the amino accepter KAPA, and how the enzyme 
retains specificity in the recognition of these two different substrates is only partially 
understood. An Mtb BioA X-ray structure with bound PLP co-factor was first reported by 
Dey et al. in 200821 (PDB-id 3BV0); the resolution and structure quality was improved by 
Geders et al. in 2011 (PDB-id 3TFT)25. Dey et al. also worked toward substrate bound 
Mtb BioA structures using X-ray crystallography. Unfortunately, they were not able to 
obtain Mtb BioA complex structure with the presence of SAM or KAPA in the active site. 
Using a H315R single site mutant Mtb BioA protein and an unreactive SAM analog 
sinefungin, they were able to capture a complex structure (PDB-id 3LV2)21. Based on the 
comparison of this structure to an E. coli BioA complex with KAPA (PDB-id 1QJ3)26, 
Sacchettini and co-workers have proposed that Mtb BioA catalyzes the transamination 
by an induced fit mechanism that relies upon active site conformational changes that 
accommodate structurally different substrates21. Although conformational details of Mtb 
BioA catalysis are yet to be investigated, this induced fit mechanism suggests that 
substantial conformational changes must occur during the catalytic cycle. This 
necessary capacity for change in the active site conformation makes it challenging to 
design Mtb BioA inhibitors and predict ligand binding using computational modeling 
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methods, particularly based on homology models derived from structures from other 
species. 
 
1.2.2 Current status of Mtb BioA inhibitor development 
Limited efforts to identify selective inhibitors of Mtb BioA have been reported. 
Amiclenomycin (ACM), a natural product extracted from Streptomyces strains, and a 
simplified derivative were identified many years ago as mechanism-based inhibitors of 
Mtb BioA23,27. ACM showed good activity against Mtb cells, but failed in animal models27 
likely due to its low chemical stability28.  
 
More recently, mechanism-based inhibitors based on ACM (compound 1, Figure 1.4) 
with improved chemical stability have been described, but the stability comes at the 
expense of lower potency29. The design of this new mechanism-based inhibitor was 
based on the hypothesis that by introducing a heteroatom into the 1,4-cyclohexadiene, 
the aromatic stabilization energy of this ring would decrease so that the compound’s 
chemical stability against self-aromatization would increase. Biochemical evaluations 
and structural characterization confirmed that compound 1 is also a mechanism-based 
inhibitor with a two-step mechanism of inactivation (Figure 1.5). It possesses a 
comparable kinact to ACM; however, the KI value is 26-fold higher. This indicates that the 
initial binding of compound 1 with Mtb BioA in the active site is weak. The second-order 
rate constant for inactivation kinact/KI of 1 is 346 M-1 min-1. It is a potential lead compound 
which can be further developed for therapeutic purposes.  
 
For the purpose of understanding the inhibitory mechanism of compound 1, our group 
produced complex X-ray crystal structures of BioA before and after the inactivation with 
compound 1 (PDB-ids 3TFT and 3TFU). The post-inactivation complex shows complete 
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cleavage of the internal aldimine and the formation of a covalent adduct, which coincides 
with the proposed mechanism. Structural studies with the post-inactivation complex has 
brought to our attention the flexibility of the BioA active site; a Trp64 side chain flipped to 
a new position to favor the binding of the aromatized ring in the adduct complex25. 
Nevertheless, much remains unknown about the flexibility of the active site and its 
capacity for binding ligands. Unanticipated conformational changes can make it difficult 
to predict ligand binding using the BioA holo structure as an initial model. A need 
therefore remains to better understand the conformational dynamics of BioA. More 
diverse chemical scaffolds that bind BioA active site can help characterize the flexibility 
of the active site, as well as to serve as starting points for BioA inhibitor design. A 
fragment-based approach can serve these purposes efficiently. 
 
1.3. Fragment Based Inhibitor Design 
 
1.3.1 Fragment-based drug design vs. High throughput screening 
Fragment-based drug design (FBDD; also known as fragment-based lead discovery, 
FBLD) is a concept that has been rapidly popularized in the last decade. FBDD’s main 
objective is to identify fragment hits (small molecule ligands) of the targets and design 
larger potent compounds by modification of these hits. “Fragment” is a concept to 
differentiate the small molecules used in the fragment screening from those often used 
in traditional high throughput screening (HTS). FBDD affords some distinct advantages 
over HTS. First, FBDD screening covers a relatively large chemical space using a small 
number of compounds. Unlike HTS, FBDD usually begins with a screen of several 
hundred or thousand compounds as combinations of fragments that cover a larger 
chemical space more efficiently than HTS. Second, fragment screening has a higher hit 
rate than traditional HTS; large complex molecules used in HTS must simultaneously 
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fulfill the requirements of many different sub-sites, while small a fragment molecule only 
need to match one. Approximately half of HTS fails because there are no initial hits 
discovered as starting points30. 
 
The disadvantages of FBDD are also not trivial. First, fragment hits often have low 
binding affinities to targets (high micromolar, µM or even millimolar, mM); this increases 
the difficulty in detecting fragment hits. Fragment hits binding affinities are often too 
weak to show measurable inhibition in a typical biochemical activity assay. Advanced 
biophysical techniques including Differential Scanning Fluorimetry (DSF), Surface 
Plasmon Resonance (SPR), Isothermal Titration Calorimetry (ITC) and Saturation 
Transfer Difference NMR (STD-NMR), are reported to be sensitive enough to detect the 
binding of small molecules with dissociation constants (KD) as high as 1 mM.31 However, 
to detect hits with low binding affinities, compound solutions need to be prepared at very 
high concentration; this requires that the fragment compounds also have very high 
solubility. Second, while sensitive biophysical methods can detect binding, they can 
provide no discimination between relevant binding (that which has the potential to inhibit 
protein biological function) from indiscriminant and unimportant binding.  The relevance 
of binding to function is typically inferred only following structural characterization of the 
binding, mode.   Structural characterization and screening must be applied together to 
prioritize fragment hits for further effort. The third disadvantage is also related to the low 
binding affinity of the fragment hits. Although it is easier to find initial hits from fragment 
screening than HTS, the success rate of developing the fragment hits into lead 
compounds is low.31 Some fragments with very low binding affinity to a protein might not 
be a good starting point for further potency optimization.32 Because fragments are by 
definition small molecules, and the size of a compound can potentially influence the 
binding affinity, a measurement of ligand efficiency (LE) is used as a comparative 
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measure of the value of fragment hits.33 Ligand efficiency is defined as the binding 
energy per heavy atom of a ligand compound with its target protein.34 A compound with 
a KD of 10 nM and a molecular weight of 500 Da (about 38 non-hydrogen atoms) would 
have a LE of 0.29 kcal/mol/heavy atom. Thus, preference is often given to fragments 
with a ligand efficiency greater than 0.3 kcal/mol/heavy atom to start further 
optimization.33 
 
1.3.2. Strategies for Fragment Lead Optimization 
In a typical procedure of FBDD, fragment screening is first applied to identify small 
molecules that bind the potential drug target. This initial screen usually utilizes some 
biophysical technique. Initial screening is then followed by structural characterization 
using X-ray crystallography or NMR. Initial screening is more efficient than direct 
structural observation, so it can be used to reduce the number of compounds that must 
be examined structurally. The three dimensional visualization of fragment binding is very 
important because fragment molecules are small, and they usually only occupy a sub-
site of the binding site with very moderate initial binding affinity. The detailed structural 
characterization of the fragment binding is often used to guide the further optimization. 
To arrive at a lead compound from fragment hits, different strategies for fragment 
optimization have been developed. These strategies may generally be grouped into two 
categories: “fragment linking” and “fragment growing”. The fragment linking strategy can 
be used when two fragment hits are discovered to bind in adjacent sub-sites of the 
protein. Ideally, the two fragments can be combined to form a larger molecule with 
higher affinity by contriving a chemical linker that joins the two fragments without 
perturbing the binding of each; in the real world, fragment linking is a very challenging 
strategy. There are several requirements for the fragments that are linked together. First, 
the distance between the two binding fragments should be proper: if the fragments are 
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too close together, there might not be space to place the linker, but if the fragments are 
too far away, the long linker might result in too large a molecule. Second, the 
incorporation of the linker cannot affect any important interactions of the fragments with 
the protein or create strain that changes the fragment binding conformation. Third, the 
linker itself should not introduce unfavorable interactions with the target. These 
requirements make it difficult to successfully employ a linking strategy31,35. For the 
reasons above, there are few successful examples of lead compound generation by 
fragment linking since it was first introduced by Shuker et al. in 199636. There are several 
successful examples of fragment linking involving protease targets31,37-39, as proteases 
often have extended binding sites. In one example, Howard et al. discovered thrombin 
inhibitors with nanomolar binding affinity by fragment linking40. They used X-ray 
crystallographic screening and identified fragments that bind to the S1 pocket and S2-S4 
pockets respectively. Fragment linking has also been successfully applied to 
acetylcholinesterase, which has a deep, gorge-like active site41. In 2004, Harry et al. 
designed an inhibitor of acetylcholinesterase by linking fragments that bind in the active 
site and an adjacent cation binding site41.  
 
Compared to fragment linking, fragment growing is more often used for lead discovery. 
In a fragment growing strategy, a stepwise extension of the fragment is often performed 
to gain additional interactions with the protein target42-44. In some real FBDD cases, the 
distinction between “linking” and “growing” can be unclear. In the initial fragment 
screening, when there are multiple fragments binding in the same binding site but 
making different interactions with the protein, one commonly used strategy is to merge 
the molecular features of different fragments to devise compounds with more 
interactions and better binding affinity35. Fragment binding information can also be used 
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for the optimization of lead compounds by scaffold hopping, where new ligands are 
created by an exchange of chemical features between existing ligands.45  
 
1.3.3. Important experimental components for FBDD 
A fragment-based drug discovery approach necessarily begins with empirical fragment 
screening conducted to identify a collection of small molecule fragments that bind to the 
target.   To successfully complete a fragment screen, several experimental components 
must be in place including: 1) A good “fragment library”; 2) a sensitive and efficient 
biophysical method to detect compound binding, and 3) a means to structurally 
characterize ligand binding. We will elaborate on these points one by one. 
 
1.3.3.1. Fragment libraries 
The composition of the fragment library is crucial for success in fragment screening. In 
general, there are two types of fragment libraries:  diverse libraries and focused libraries. 
Diverse libraries are designed to efficiently cover a large chemical space for more 
general screening purposes. Diverse fragment libraries are often used for the initial 
exploration of possible binding features of the targets. A successful fragment screen 
relies heavily on the quality of the fragment library. An ideal fragment library should 
possess the following features. First, the compounds in the library need to have superior 
physicochemical properties to allow room for further development into molecules with 
suitable ADME attributes.46 The “Rule of 3” is a widely accepted criteria for fragment 
physicochemical properties (the molecular weight is less than 300 Da; there are no more 
than three hydrogen bonding donors or acceptors in the molecule; the partition 
coefficient (clogP) is to be less than three; and the number of rotatable bonds should be 
no more than 3).35,47 Second, a general purpose fragment library needs to cover a 
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considerably large chemical space.48 Clustering software is available to assist in design 
of highly diverse libraries.49,50 Third, for the purpose of drug design, it is often beneficial 
to start with pharmacophore enriched molecules.48  
 
A target-focused library is often specially designed around a certain chemical scaffold or 
a key pharmacophore and used for targeting a particular protein or protein family. The 
design of a focused library can be assisted by computational tools.51 Libraries can either 
be designed based on the knowledge of the targets52 or from ligand similarity search 
using fingerprints of molecules53.  There are multiple examples of successful 
implementation of a focused library in drug discovery. In 2005, Grasberger et al. 
screened a large benzodiapepine library (> 300,000 compounds; which is used as a 
collection of peptide mimetics for probing possible protein-protein interaction sites) and 
discovered a novel series of benzodiazepinones as HDM2−p53 interaction antagonists.54 
In a nice example from 2002, Liebeschuetz et al demonstrated use of a very small but 
hit-rich library of benzylamido analogs that were already known to preferentially bind in 
the S1 subsite of Factor Xa.55   
 
For the Mtb BioA case, because there is limited knowledge of structural features of 
bound ligands, a general purpose library is appropriate. We used a diversity core set of 
Maybridge Ro3 library (1000 compounds) for screening purposes. The fragments in this 
library have many good features. First, they follow the “Rule of 3”. Second, they have 
assured solubility in both DMSO (200mM) and PBS buffer (1mM). Third, the library is 
computationally engineered to have diversity; it is pharmacophore rich but includes 
structures with low complexity.56    
 
1.3.3.2. Biophysical screening tools used in FBDD 
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Since small molecular fragments may not be expected to possess measurable activity in 
biochemical enzyme assays, fragment screening must be conducted with sensitive but 
efficient biophysical methods that can be applied to detect small molecule binding.   
Several methods have been widely used in fragment screening applications. 
 
Differential Scanning Fluorimetry (DSF) can be used to detect small molecule binding 
to proteins and has been used in fragment screening.57-59 This is based on a fact first 
introduced by Koshland in 1958 60, that binding by a small ligand may cause 
conformational changes of a protein, even regardless of enzymatic activity. Changes in 
protein stability that accompany these conformational changes can shift the midpoint of 
the heat-induced transition from the folded to unfolded state (the “melting temperature” 
or Tm). Unfolding can be monitored by DSF if a fluorescent dye sensitive to the 
appearance of unfolded protein is included in the solution along with the potential ligand. 
DSF is a medium-throughput assay. By using a real time-PCR (RT-PCR) machine, up to 
384 fragments can be screened simultaneously in one plate61.  
 
There are varieties of choices for the fluorescent dye used in DSF. Generally speaking, 
there are three features of the dyes: 1) the intrinsic fluorescence of the dye must be 
quenched by water in solution; 2) the dye binds nonspecifically with hydrophobic 
residues; 3) the fluorescent property of the dye changes significantly upon binding with 
the hydrophobic residues. Because of the usage of the dye, DSF cannot be considered 
a completely label free method. However, the protein is not pre-labeled before the 
experiment, and the possible effects of the dye on the protein and small ligands can be 
characterized using several control experiments. DSF can be used to evaluate binding of 
small ligands with a KD value of 10-9 to 1 M. It provides a huge sensitivity range 
compared to other techniques. DSF also consumes a relatively small amount of protein 
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(about 0.4 µg/experiment).  DSF does not provide information about binding sites or 
stoichiometry, so a structural characterization of hits is a necessary to confirm relevance.  
DSF can also produce both false positive and false negative results. Although ligand 
binding may induce either a positive or negative Tm shift, most investigators have 
typically focused only on ligands that stabilize the protein to unfolding.62 We will 
elaborate on this point more in later discussion. 
 
Saturation Transfer Difference NMR (STD-NMR) is a ligand based NMR technique. It 
is one of the most popular techniques in use for fragment screening38,63, and was in fact 
the first biophysical method used in a fragment screening paradigm.36 STD-NMR utilizes 
the fact that a small molecule has a much faster relaxation time than a large molecule, 
and that the spin excitation on a large molecule can be transferred to a bound small 
molecule and used to detect ligand binding. In a typical STD-NMR experiment, two NMR 
signals are given: on-protein resonance frequency and off-protein resonance frequency. 
By subtracting the two NMR spectra signals, the signal of the bound small ligand will be 
detected. Rapidly evolving NMR capabilities (higher resolution, auto sampling systems 
etc.) has allowed STD-NMR screening to be a high-throughput screening technique. 
First, multiple small molecules can be screened in one single experiment as long as their 
spectra are differentiable. Second, auto sampling systems and shortened scanning time 
for each experiment make STD-NMR quite efficient. Another great advantage of STD-
NMR is that it is a completely label free experiment that reflects the solution state of the 
protein; the experiment can be performed under a steady temperature of choice to best 
mimic the physiological conditions. The detection range of STD-NMR is 10-8-10-3M: 
binding affinities that are too tight or too loose can cause problems based on the 
underlying principle of this method. STD-NMR consumes a relatively high amount of 
protein in a single experiment (up to 50-75 µg)64. Like DSF screening, STD-NMR also 
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cannot provide information where compounds bind. However, there is one unique piece 
of information STD-NMR can provide that is not provided by other biophysical screening 
techniques, the epitope maps. The strength of the saturation transfer signal of a 
particular atom in the small molecule is negatively correlated to its distance from the 
protein: the closer the atom is towards the protein, the stronger its saturation transfer 
signal is. Using this feature, relative distances of the detected atoms from the protein 
can be mapped out. This map can be informative as it shows which part of the small 
molecule is more important for binding. 
 
Surface Plasmon Resonance (SPR) is another popular technique for fragment 
screening.65-67 In SPR, the protein is immobilized on a metal surface of a specially 
designed chip, and the ligands flow past the surface during the experiment. Ligand 
binding can cause changes in reflectivity properties of this surface. These changes are 
related to some properties of the surface, as well as the mass of the protein and ligands. 
With the current techniques SPR is not a high throughput screening method, but it can 
be used to screen thousands of compounds needed for fragment screening. SPR 
consumes very low amount of protein, because once the protein is immobilized on a 
surface of a chip, the chip can be used for screening of many different ligands. There are 
in general two different methods for protein immobilization: the covalent coupling 
chemistry and unidirectional immobilization. Covalent coupling chemistry uses the 
reactive groups on the surface of the protein (i.e. amine, thiol etc.) to form covalent 
linkage with the surface. The reacting group is randomized so the orientation of the 
protein is also randomized. Unidirectional immobilization tethers the protein to the 
surface in a certain orientation. It utilizes some site-specific immobilization tool such as 
antibody and biotinylation to build a more homogenous protein surface. Neither of these 
immobilization methods can retain the proteins’ natural behaviors, and this might cause 
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some false screening results. The detection range of SPR experiment is about 10-3-10-9 
M, and it is dependent on the solubility of the ligands. SPR can be used to study the 
kinetics of the ligand binding. It gives a direct measurement of the association rate 
constant kon and dissociation rate constant koff, SPR is also widely used to characterize 
the ligand binding affinity, especially for ligands with low binding affinities. 
 
1.3.3.3. Structural validation tools for fragment screening 
NMR is often used to validate fragment binding. Target-based approaches were 
developed first to characterize ligand bindings.68 This approach compares 2 dimensional 
NMR spectrum of the protein alone with the spectrum of the protein in presence of the 
ligand. Changes in protein chemical shifts indicate binding. Provided chemical shift 
assignments have been completed for the protein structure, the binding site can be 
located by identifying protein residues with chemical shift changes. This target-based 
NMR technique has several advantages. First, this is a very robust method to validate 
ligand binding and it can provide some structural information about binding mode. 
Second, using NMR, the experiment can be designed under solution conditions that best 
mimic the proteins’ endogenous conditions. Third, it is almost the only way to analyze 
structures of proteins that are difficult or impossible to crystalize. There are also caveats 
of this method. First, this experiment consumes a large amount of protein.69 In some 
cases hundreds of milligrams are used for one experiment.70 Second, this approach has 
a limit for the protein size (30-40 kDa)68. This is because 15N enriched protein needs to 
be expressed, and chemical shift assignment for the entire protein structure is required. 
To overcome these technical problems, ligand based NMR approaches have emerged 
recently. These approaches can be used to acquire ligand NMR spectrum and detect 
ligand binding by observing ligand chemical shift changes rather than protein; however, 
they do not provide structural data.  
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X-ray crystallography may be used to validate the binding of fragment hits discovered 
from the screening assays. Getting a complex structure model with X-ray crystallography 
is considered to be a “gold-standard” for the validation of fragment binding. A crystal 
structure can provide a three-dimensional binding mode of the ligand with the protein. It 
can be used to distinguish specific binding from nonspecific binding; it can also show if a 
ligand is binding in the active site or in some allosteric or irrelevant sites. However, there 
are potential liabilities of crystallography: diffraction analysis can only be conducted 
following a successful search for crystallization conditions. Protein crystallization 
solutions are also highly concentrated, or may require high ionic strength precipitants 
that can often cause problems with the co-crystallization of compounds with poor 
solubility. For this project, because conditions were known for the production of high 
quality crystals of BioA, X-ray crystallography was selected as the method for structural 
validation and structure-based fragment optimization. Information from X-ray 
crystallography provides invaluable information to guide the molecular design of new 
inhibitors.  
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Figure1.1. Structures of some important TB drugs 
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Figure 1.2. Mtb BioA biotin biosynthesis pathway. 
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Figure 1.3. Catalysis of DAPA synthesis by BioA.  
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Figure 1.4.  Recent Mechanism-Based Inhibitor from Natural Product Modification. 
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Figure 1.5. Inactivation mechanism of compound 1 by adduct formation with the 
BioA PLP co-factor. 
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Chapter II: Crystallographic studies of Mtb BioA with substrate 
KAPA 
Acknowledgement: Some material included in this chapter is excerpted from previously 
published work [ Dai, R. et al, 2014. "Inhibition of Mycobacterium tuberculosis 
Transaminase BioA by Aryl Hydrazines and Hydrazides ". ChemBioChem. 15(4):575-
586]. This includes sections 2.2.4, 2.3.2 and figures therein.  Ran Dai and Barry Finzel 
contributed equally in writing this published work, with assistance from other authors. 
Permission to use this copywrited material has been granted by John Wiley & Sons. 
 
2.1 Introduction 
 
2.1.1. Review of previous Mtb BioA production and crystallization efforts 
In 1998, Cole et al. published their work describing the complete genome for 
Mycobacterium tuberculosis.71 As we have discussed in Chapter 1, enzymes involved in 
the biotin synthesis pathway were identified as promising as drug targets20 and BioA, the 
enzyme that catalyzes the second step, is of particular interest since it is both 
structurally21 and functionally72 well characterized.  
 
In 2010, the first effort toward overexpression, purification and crystallization of Mtb BioA 
was reported by Dey et al.21 For overexpression, they constructed a plasmid by cloning 
bioA(Rv1568) into a pET28b vector with the TEV site using the NdeI and HindIII sites. 
IPTG was used to induce the BioA overexpression. Purification was accomplished with a 
Histrap nickel column using a tris(hydroxymethyl)aminomethane (Tris) buffer system. 
Crystallization of BioA was achieved under a PEG-based condition using Tris as the pH 
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buffer (10% PEG 8000, 0.1 M Tris buffer pH 7.0, and 0.1 M MgCl2). Diffraction data was 
collected to 2.2 Å resolution using a home X-ray source21. 
 
In 2011, Wilson et al. published an alternative plasmid construct for BioA 
overexpression73. They first cloned bioA(Rv1568) into a pET28b vector including a TEV 
site using the NdeI and HindIII sites. Then they cloned bioA along with the RBS and His 
tag from pET28b into a pUC18 vector to yield a new plasmid pCDD126; pCDD126 is 
controlled by a lac promoter so the protein expression does not require induction by 
IPTG.  
 
In 2012, Geders et al. published an improved protocol for BioA purification and 
crystallization74. They used differential scanning fluorimetry (DSF) to monitor the 
homogeneity of the protein and discovered that by using 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) as the pH buffer rather than Tris, and tris(2-
carboxyethyl)phosphine (TCEP) as reducing reagent instead of dithiothreitol (DTT), the 
homogeneity of the BioA protein can be significantly increased. Removal of Tris as the 
buffer in purification increased the purity of BioA final product, because Tris can 
potentially react with the PLP co-factor of BioA.74 In their purification protocol, an 
additional size exclusion column (HiPrep 26/60 Sephacryl S200 HR column from GE 
healthcare) was used after the Histrap nickel column for extra purification. It was also 
reported that by using HEPES as the pH buffer in crystallization, the quality of the BioA 
holo crystals could be enhanced so that diffraction data with higher resolution could be 
obtained 25,74. Methods for Mtb BioA expression, purification and crystallization are 
compared in Table 2.1. 
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In our research, the expression system developed by Wilson et al. and the optimized 
BioA holo protein purification and crystallization protocols were used to achieve the best 
protein quality and crystallography results. Detailed procedures are described in section 
2.2.
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2.1.2. Structural studies of the Mtb BioA catalytic cycle 
As discussed in Chapter 1, BioA catalyzes amino transfer reaction via an induced-fit 
mechanism 26 28. Detailed structural descriptions of the conformations of the enzyme 
intermediates in the catalytic cycle are very limited. Dey et al. have described a complex 
structure of a mutated construct of BioA with a SAM analogue sinefungin in the active 
site (pdb id 3LV2)21. However, no KAPA bound Mtb BioA structures were available to 
study the detailed conformational changes in the active site in the catalytic cycle. A 
KAPA bound E.coli BioA model (pdb id 1QJ3)26 and a KAPA bound B. subtilis BioA 
model (pdb id 3DU4) were used to predict Mtb BioA KAPA binding. However, E.coli BioA 
only has 48% sequence identity with Mtb BioA75 and B. subtilis BioA model has only 
32% identity with Mtb BioA21. To better understand the detailed active site conformation 
of Mtb BioA when KAPA is bound, we generated and studied the Mtb BioA KAPA 
complex using X-ray crystallography (pdb id 4CXQ)62.  
 
2.2. Mtb BioA expression, purification and crystallization 
 
2.2.1. Mtb BioA expression and purification 
The experimental procedure for Mtb BioA expression and purification is as described by 
Geders et al. 74 
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2.2.2. BioA holo protein homogeneity assessment using DSF 
Differential scanning fluorimetry was performed using a protocol established by Todd 
Geders 74. A total volume of 40µL solution was used for one DSF experiment. BioA was 
diluted on ice to a final concentration of 0.1 mg/ml in a solution containing 25 mM 
HEPES pH 7.5, 50 mM NaCl and 5X SYPRO Orange (Life Technologies). To generate 
the DSF melting curve, fluorescence was measured using the FRET channel of the 
CFX96 between 298 and 368 K with 30 s incubation per 1°C temperature increase.  
 
2.2.3. Mtb BioA holo protein Crystallization 
The crystallization conditions used were as described by Geders et al.21 74. These BioA 
holo protein crystals were used for crystal soaking experiments for the fragments in 
chapter III, and to prepare seeds for all crystallization experiments in this thesis. The 
seeds were prepared by crushing small crystals from previous vapor diffusion drops. To 
prepare BioA seeds, a 2 µl drop of crystals was diluted in 100 µl reservoir solution (15% 
PEG 8000, 100 mM HEPES pH 7.5, 100 mM MgCl2) and crushed thoroughly; the seed 
concentration of this solution was defined as 1:1. By consecutive 10 fold d ilution of the 
1:1 seed solution, 1:10, 1:100, 1:1000 and 1:10000 seed solutions were made. From our 
experience, 1:1000 seed concentration should be used for optimal crystallization results. 
Crystals appear in the drop within 24 hours and grow to their full size in 72 hours. BioA 
holo crystals were protected by transferring to a cryo solution (15% PEG400, 15% PEG 
8000, 100 mM HEPES pH 7.5, 100 mM MgCl2) and then they were flash frozen in liquid 
nitrogen. Because crystal nucleation and growth always occurs with uncertainty, 
crystallization is always conducted as a series of experiments in which precipitant and 
seed solution contributions are varied systematically to surround the anticipated 
optimum conditions. Detailed crystallization conditions are listed in Table 2.2. The BioA 
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holo crystals prepared in this way were used for soaking with compounds to obtain 
complex structures.  
  34 
 
Table 2.2. Example of Mtb BioA crystallization conditions.  
 
A 9%-14% (w/v) gradient of PEG concentration and two different seed concentrations 
(1:1000 and 1:5000) were tested. 
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2.2.4. The BioA KAPA complex structure determination 
A co-crystallization technique was used to obtain the BioA KAPA complex structure. 
Protein solution (10 mg/mL in 25 mM HEPES pH 7.5, 50 mM NaCl, 0.1 mM TCEP) was 
mixed with reservoir solution containing KAPA (9–18% PEG 8000, 100 mM HEPES pH 
7.5, 100 mM MgCl2, and 5 mM KAPA) and a 1:1000 seed solution in a 4:3:1 ratio. 
Crystals appear in the drop within 24 hours and grow to their full size in 72 hours. BioA-
KAPA co-crystals were protected by transferring to a cryo solution (15% PEG400, 15% 
PEG 8000, 100 mM HEPES pH 7.5, 100 mM MgCl2, and 5 mM compound) and then 
flash frozen in liquid nitrogen.  
 
The diffraction data was collected at 100 K using synchrotron radiation with a Dectris 
Pilatus 6M Pixel Detector on beamline 17-ID (IMCA-CAT) at APS, Chicago, United 
States. The data were processed, integrated, and scaled with XDS76 and SCALA using 
the autoPROC scripts available at IMCA-CAT. Summary data collection and processing 
statistics are given in Table 2.3. The structures were solved by molecular replacement 
using Phaser77 in the CCP4 package78 using atomic coordinates from PDB code 3TFT 
as a search model.25 Refinement and model building was done using REFMAC579 and 
coot80. The figures were prepared with PyMOL (The PyMOL Molecular Graphics 
System, Version 1.5.0.4 Schrödinger, LLC.). Structures were superimposed for analysis 
and displayed using the shared BioA-PLP overlay method of the DrugSite server81. 
Atomic coordinates and diffraction data have been deposited in the Protein Data Bank 
with accession code 4CXQ. 
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Table 2.3. Summary of Crystallographic Data. 
PDB code 4CXQ 
Ligand KAPA 
   
Data collection site IMCA-CAT 
Detector DECTRIS PILATUS 6M 
Wavelength (Å) 1.000 
Space group P212121 
Cell dimensions  
    a, b, c (Å) 62.553, 66.149, 205.294 
    α,β,γ (°) 90, 90, 90 
molecules per ASU 2 
Resolution (Å) 55.60-1.80(1.806-1.800) 
Rmerge 0.075(0.432) 
I/σI 16.6(4.0) 
Completeness 98.9% (98.3%) 
Multiplicity 6.5(6.5) 
No. observations 515130 
No. unique reflections 79062 
   
Refinement  
    Resolution (Å) 102.65-1.80 
    Rwork/Rfree 16.8/20.0 
    No. atoms 7184 
    No. water 527 
    No. ligand molecule 2 
    No. PLP molecule 2 
    No. other molecule 5 
Ramachandran plot  
    Favored 765 (95.6%) 
    Allowed 29 (3.6%) 
    Disallowed 6 (0.8%) 
R.m.s deviations   
    Bond lengths (Å) 0.009 
    Bond angles (°) 1.24 
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2.3 Results and discussion 
 
2.3.1. Optimization of BioA purification and crystallization procedures 
Higher quality and yield of holo BioA was obtained by using the optimized purification 
protocol by Geders et al (2012): the yield of the protein was increased to 10-15 
milligrams per liter of cell culture. Geders has repeated a previous protocol by Dey et al. 
(2010) and only 1.5 milligrams per liter of cell culture was obtained. Wilson et al. also 
reported a 1.5 milligrams per liter of cell culture yield using his expression and 
purification method73. In these previous protocols, an anime containing buffer 2-amino-2-
(hydroxymethyl)-1,3-propanediol (Tris) and thiol containing reducing agent dithiothreitol 
(DTT) was used. Also, no supplemental PLP was added to the final protein solution to 
ensure PLP saturation. Holo BioA protein has its PLP cofactor covalently linked with the 
terminal amino group in Lysine 283 in the protein active site, forming a Schiff base. This 
linkage can be broken when extraneous reactive compounds (amine or thiol compounds) 
come to compete. In Geders’ optimized purification, the reactive components were 
removed from the purification buffers, and extra amount of PLP was supplemented to 
ensure protein homogeneity during the purification procedure. These modifications 
greatly increased the yield and quality of the active form of the protein, and helped to 
increase the quality of the crystals formed in crystallization74. 
 
 2.3.2. The KAPA complex structure  
As previously described, Mtb BioA is a functional homodimer with two catalytic sites that 
lie about 18 Å apart. Each active site is comprised of loops contributed by both 
polypeptide chains, including residues Pro24-Ser34, Ser62-Ala67, Arg156-Asp160, 
His171-Arg181, Gln224-Gly228, Arg400-Arg403, Met87ʹ′-His97ʹ′, and Ala307ʹ′-Asn322ʹ′ 
(Figure 2.1A). Residues tagged with a prime originate in the alternate chain. Ser125, 
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Asp254, Lys-283 and Thr-318ʹ′ all make specific interactions with the PLP, are strictly 
conserved in all Class I transaminases, and adopt a conserved conformation in all BioA 
structures reported to date.  While residues 25–33 are disordered in the original BioA 
structure reported by Dey et al. (PDB-id 3BV0),21 Tyr25 is well-ordered in the structure 
reported as a “pre-reaction” conformation in our study of an irreversible inhibitor of 
BioA,25  and the side chain hydroxyl of the tyrosine lies H-bonded to Asp-160 and poised 
to interact with substrates. This structure (PDB-id 3TFT) will stand to represent the holo 
enzyme (PLP-bound resting state) conformation in the remainder of this discussion. In 
this state, the PLP is covalently bound to the side chain amine of Lys283, a well-known 
feature of transaminases (Figure 2.1A). 
 
To provide a more reliable picture of different conformational states promoted by 
substrate binding, we determined the structure of the KAPA-bound enzyme at 1.8 Å 
resolution (Table 2.3). At this resolution we can confirm from the carbon hybridization 
and stereochemistry that, as expected, KAPA is bound , and not the product DAPA 
(Figure 2.1C). KAPA binds to the holo enzyme much as predicted, and induces no 
significant conformational changes to binding site residues, except for an inward shift of 
the guanidinium of Arg400, which moves in to pair against the KAPA carboxylate and 
cap the binding pocket (Figure 2.1D).  Such a shift had been predicted21 based on 
similarity to the E. coli enzyme structure.26 The KAPA amino group does not displace the 
lysine bond to the PLP, but instead sits between the Tyr25 OH and the PLP phosphate, 
making strong hydrogen bonds to both. Other H-bonds to Tyr-157 OH and the carbonyl 
O of Gly316ʹ′ complete the tetrahedral H-bonding around the protonated amine (Gly316ʹ′ 
is contributed by the alternate chain of the BioA homodimer). The ketone O of KAPA 
makes no hydrogen bonds, but is positioned just 3.4 Å from the Nz of Lys283, which 
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remains covalently bound to the PLP.  The close packing of the β-methylene group 
against the aromatic ring of the Trp64 indole adds a strong hydrophobic contact to 
enhance binding. 
 
Structures of Mtb BioA with substrates SAM and KAPA have not been previously 
reported, but detailed homology-based conceptions of substrate binding have been 
proposed based on studies with substrate surrogates (e.g., SAM analog sinefungin; 
PDB-id 3LV2), and homologous proteins (e.g., Bacillus subtillis BioA co-structure with 
KAPA, PDB-id 3DU4).21 Despite the fact that the two substrates are quite different, both 
appear likely to occupy the same binding site, comprising a largely hydrophobic pocket 
between aromatic side chains of Trp64, Trp65, Tyr25 and Phe402. The adenosine of 
SAM likely extends further (Figure 2.1B), but apart from the side chain of Arg400, the 
specific groups that interact with the nucleobase are not convincingly known because of 
disorder observed in surrounding loops (residues 23-34, and 309-317) in many of the 
homolog and BioA crystal structures.  This flexibility may be an important characteristic 
of an enzyme that must adapt to diverse substrates during the catalysis of 
transamination. 
  
Dey et al. have reported a B. subtilis  BioA-sinefungin complex.21 In their report, Tyr25 is 
observed in a different conformation with the side chain rotated 180° to contact the 
adenosine base (Fig 2.3B). They conclude that π-stacking between the adenosine and 
this tyrosine or the phenylalanine found in other bacterial species is important feature 
stabilizing SAM binding in Mtb BioA. While we also have no specific data to contradict 
this hypothesis, we do not find their arguments compelling. The geometry for effective π 
-stacking in the sinefungin complex structure is poor, as the phenol ring of Tyr25 is tilted 
45° from the plane of the adenosine; the Tyr25 OH makes the closest contact to 
  40 
 
sinefungin in this complex, and this is not indicative of favorable π-stacking. From our 
own experience, in all of the complex structures we have obtained for BioA (17 
structures), Tyr25 is always oriented as seen in the KAPA or holo complexes, and never 
as seen in the sinefungin complex (Figure 2.1). The B. subtilis BioA complex (PDB-id 
3LV2) is a co-crystal with a H315R mutant, and the histidine occupies the position taken 
by the side chain of Tyr25 in the wild type enzyme (Figure 2.2). It is possible that the 
shift in Tyr25 observed in the sinefungin BioA complex is a consequence of this mutation, 
rather than sinefungin binding.  
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Figure 2.1. A comparison of the BioA complex with KAPA to other structures.  
 
A) The holo (PLP-bound) Mtb BioA structure (PDB-is 3TFT)74. The enzyme resting state 
with PLP covalently linked to K283. B) Sinefungin (SFG)-bound structure of B. subtillis 
BioA (PDB-id 3LV2) complex21. C) 2Fo-Fc electron density (1σ) for KAPA, PLP, and 
Lys283. D) Detail of KAPA binding vicinity.62 
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Figure 2.2 KAPA bound Mtb BioA  (PDB-id 4CXQ; green) overlaid with SFG bound 
H315R Mtb BioA (PDB-id 3LV2; orange, some residues following Y25 are disordered in 
3LV2 so they are not drawn in this figure) 
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2.4. Conclusion 
 
In this chapter, we described the optimized Mtb BioA expression, purification, 
crystallization, as well as the homogeneity validation using DSF. We have prepared Mtb 
BioA at high yield (15 mg/L culture). We obtained protein with nice homogeneity and 100% 
PLP occupancy after purification. Using the protein we prepared, we were able to 
increase the crystal diffraction resolution to beyond 1.7 Å.  The reproducible production 
of robust holo crystals is necessary to effectively and efficiently validate and characterize 
bound small molecules that will be identified by fragment screening. 
 
Details of the induced fit mechanism of BioA catalytic cycle are yet to be fully understood; 
especially regarding how active site conformational changes occur to accommodate two 
structurally dissimilar substrates. In this chapter, we described the first complex crystal 
structure of Mtb BioA with its substrate KAPA. This structure clearly delineates the 
substrate binding site, and shows ways in which the protein conformation can adapt in 
order to accommodate different substrates (Arg 400 inward shift to make polar 
interactions with KAPA). The Mtb BioA-KAPA complex structure has added to an 
understanding of the enzymatic mechanism of BioA. 
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Chapter III: BioA lead identification by fragment screening 
 
Acknowledgement: Some material included in this chapter is excerpted from previously 
published work [Dai, R. et al, 2014. "Inhibition of Mycobacterium tuberculosis 
Transaminase BioA by Aryl Hydrazines and Hydrazides ". ChemBioChem. 15(4):575-
586]. This includes portions of sections 3.2.1, 3.3.2 and figure 3.5.  Ran Dai and Barry 
Finzel contributed equally in writing this published work, with assistance from other 
authors. Permission to use this copywrited material has been granted by John Wiley & 
Sons. The fragment DSF screening was done by Todd Geders in the lab of Prof. Barry 
Finzel. The fragment ITC experiments were done by Ran Dai with aid from Dr. Feng Liu 
(Prof. Courtney Aldrich lab); the ITC data were processed by Dr. Feng Liu (Prof. 
Courtney Aldrich lab). 
    
3.1 Introduction 
The weakness of ligand-target binding makes the identification of lead fragment 
compounds challenging.57 Very sensitive biophysical techniques, such as DSF82, STD-
NMR83, SPR65 and X-ray crystallography84, have been used routinely for screening 
fragment libraries in FBDD. These biophysical methods have been reviewed in Chapter 
I. Efforts have been made to combine different biophysical methods85, and results from 
different screening methods are rarely alike. It has been recently argued that to better 
design a fragment library screening protocol, a cascade of biophysical methods should 
be used.86  
 
For our own fragment library screening, a three-stage protocol was designed and used. 
DSF was first used to identify fragments from the 1000 compound Maybridge Ro3 
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diversity library that shift the protein melting temperature. Then, macromolecular X-ray 
crystallography was used as a structure-based validation to ensure specific binding. 
Finally, multiple biophysical methods (STD-NMR, SPR and ITC) have been used in an 
effort to determine the binding affinities of each fragment compound to prioritize them for 
further optimization.  
 
3.2 Experimental procedures for DSF fragment screening 
 
3.2.1 DSF 
The DSF screening was performed by Dr. Todd Geders in the lab of Prof. Barry Finzel. 
In a glass tube, 2475 µL of 2X master mix was made at room temperature by mixing 
125.0 µL of 1M HEPES pH 7.5, 50.0 µL of 5M NaCl, 5.0 µL of 5000X Sypro orange 
stock solution, 2295 µL of water. The 2X master mix was cooled on ice. 310 µL of water 
was distributed into each well of a single column of a 96-well U-bottom plate at room 
temperature. 19 µL of water was placed into each well of the white PCR plate held by a 
room-temperature aluminum block. 1 µL of pure DMSO was placed in each well of the 
first and last column for DMSO-only controls. Using a multi-channel P10 pipette, 1 µL of 
each fragment compound was placed into a white PCR plate. BioA protein (25 µL of 13.0 
A280) was added to the master mix. 310 µL of the 2500 µL 2X master mix was 
distributed into each well of a single column of a 96-well U-bottom plate on ice. 20 µL of 
master mix with protein was added into each well of the white PCR plate and gently 
mixed. Plates were sealed and run in the Bio-Rad CFX96 using 30 sec dwell time per 
1°C temperature increase.       
 
The DSF amplification curve was generated using Microsoft Excel. The DSF first 
derivative was calculated based on the DSF amplification curve, and the first derivative 
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curve was also generated using the software Microsoft Excel. The Maximum point of the 
first derivative was used to determine the Tm shifts. 
 
3.2.2 STD-NMR 
STD NMR spectra were obtained at 20 °C using a Bruker 700 MHz NMR spectrometer 
with a TCI cryoprobe, incorporating Z-axis gradients. Samples contained BioA protein 
(30 µM) and compound 3E3 (0.1, 0.2, 0.4, 0.6 and 0.8 mM respectively).  A one-
dimensional pulse sequence incorporating a T1ρ filter was used for the acquisition of 
STD NMR spectra. The on-resonance frequency was set to 0.8 ppm and the off-
resonance frequency was set to 30 ppm. Irradiation was performed using 50-Gaussian 
pulses with a 1% truncation and a 49-ms duration and separated by a delay of 1 ms to 
give a total saturation time (Tsat) of 1, 2, 3, and 4 seconds for each compound 
concentration. The duration of the T1ρ filter was 15 ms. STD NMR spectrum was 
acquired with a total of 6144 transients in addition to 32 scans to allow the sample to 
come to equilibrium. The spectral width was 8 kHz. Reference spectrum was taken 
under the same conditions.  
The dissociation constant (KD) was calculated from the binding isotherm of STD initial 
growth rate using an established model reported by Angulo et al.87 First, STD 
amplification factor (STD-AF) was defined as the product of STD ligand intensity and the 
ligand excess (ε) as shown in equation (1). Then, STD-AF values were plotted with 
increasing saturation time (tsat) to obtain a curve fit to equation (2) to get STD-AFmax and 
ksat values. Next, an initial STD amplification factor (STD-AF0) was calculated using 
equation (3). Finally, STD-AF0 was plotted against increasing ligand concentration to 
obtain KD using equation (4). 
STD-AF(tsat) = ε (I0 - Isat)/I0 ; where ε = [L0]/[P0]          (1) 
STD-AF(tsat) = STD-AFmax [ 1-exp(-ksat*tsat)]      (2) 
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STD-AF0 = STD-AFmax * ksat                 (3) 
STD-AF0 = ( Bmax* [L])/(KD+[L])                       (4) 
 
3.2.3 SPR 
All surface plasmon resonance (SPR) experiments were performed on a BIAcore 2000 
at 25 oC. BioA protein substrate was coupled to the flow cells on the CM5 chips by 
amine coupling following instructions provided in the Amine Coupling Kit from GE 
Healthcare. BioA was dissolved to make a 0.05 mg/ml solution containing 10 mM 
Sodium Acetate at pH=5.0 and filtered to remove particulates. The functional groups on 
the CM5 chip surface were first activated by a 7 minute injection of a freshly prepared 
1:1 mixture of 0.4 M 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide and 0.1 M N-
hydroxysuccinimide at 10 µl/min; followed by injection of the substrate (BioA) for 7 min at 
a flow rate of 10 µl/min to > 4000 RU. Remaining activated carboxyl groups on the 
surface were blocked with 1 M ethanolamine for 7 min at a flow rate of 10 µL/min. A 
PBS-P buffer containing 1x PBS at pH 7.4 with 0.005% P-20 surfactant and 5% DMSO 
was used for the following ligand binding assays. In the kinetic binding assay, 
concentration series in 1:2 dilutions were assessed for binding. A 30-second association 
phase was followed by a 300-second dissociation phase. All kinetic data were processed 
using BIAevaluation 3.0 Software. A 1:1(Langmuir) binding model was used to fit the 
data and calculate the KD values. 
 
3.2.4 ITC 
Isothermal titration calorimetry (ITC) was conducted on a GE MicroCal Auto-ITC 200 
microcalorimeter. The titration experiment was performed at 25 °C in ITC buffer (25 mM 
Hepes [pH 7.5], and 50 mM NaCl). BioA was exchanged into ITC buffer using an Amicon 
Ultra concentrator, and the final enzyme concentration was determined using the 
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Bradford assay. In the titration, compounds were individually injected into a solution of 
the enzyme. Ligand and protein concentrations were optimized. For the optimization of 
protein concentration, we started with 0.01 µM that had been used to test more potent 
BioA inhibitors, and gradually increased it. For ligand concentration, a 1:10 to 1:20 ratio 
of protein to ligand was maintained in the final system concentration. Eventually 0.1 µM 
BioA and 1.0 µM, 1.5 µM, 2.0 µM fragments were adopted as more concentrated protein 
gave rise to higher signal to noise in the experiment. The KA (the association constant in 
M-1), n (the number of binding sites per monomer) and ΔH (enthalpy) values were 
determined by ITC. The thermodynamic parameters (ΔG and –TΔS) were calculated 
using Equation 1: 
 
 ∆G=-RTInKA=∆H-T∆S (1) 
 
Where ΔG, ΔH and ΔS are the changes in free energy, enthalpy, and entropy of binding, 
respectively, R = 1.98 cal mol-1 K-1, and T is the absolute temperature. The affinity of the 
fragments for BioA is provided as the dissociation constant (KD =1/KA). 
 
3.2.5 Crystallography 
The crystallization conditions used to produce BioA holo crystals were as described in 
Chapter II. Both soaking and co-crystallization techniques were used to obtain BioA 
complex structures with fragments.  For soaking, BioA holo crystals were soaked in 
reservoir solution containing 5 mM compounds (15% PEG 8000, 100 mM HEPES pH 
7.5, 100 mM MgCl2, and 5 mM compound) for 5-60 minutes at 20 °C. 
 
Compound co-crystals were prepared in respective hanging drop vapor diffusion 
experiments conducted at 20 °C. Protein solution (10 mg/mL in 25 mM HEPES pH 7.5, 
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50 mM NaCl, 0.1 mM TCEP) was mixed with reservoir solution (9–14% PEG 8000, 100 
mM HEPES pH 7.5, 100 mM MgCl2, and 5 mM compound) and a seed solution (a 
reservoir solution containing crushed BioA crystals) in a 4:3:1 ratio (2 µL BioA protein:1.5 
µL reservoir solution: 0.5 µL crushed BioA seed solution). Crystals appear in the drop 
within 24 hours and grow to their full size in 72 hours. BioA-compound co-crystals were 
protected by briefly transferring to a cryo solution (15% PEG400, 15% PEG 8000, 100 
mM HEPES pH 7.5, 100 mM MgCl2, and 5 mM compound) using an appropriately sized 
fiber loop of a cryo pin from Hampton Research and then flash frozen in liquid nitrogen. 
Diffraction data were collected from crystals at 100 K using synchrotron radiation with a 
Dectris Pilatus 6M Pixel Detector on beamline 17-ID (IMCA-CAT) at APS, Chicago, 
United States. Data were processed, integrated, and scaled with XDS76 and SCALA88 
using the autoPROC scripts available at IMCA-CAT. The structures were solved by 
molecular replacement using Phaser77 in the CCP4 package78 using atomic coordinates 
from PDB code 3TFT as a search model.25 Refinement and model building was done 
using REFMAC579 and coot80. The figures were prepared with PyMOL (The PyMOL 
Molecular Graphics System, Version 1.5.0.4 Schrödinger, LLC.). Structures were 
superimposed for analysis and display using the shared BioA-PLP overlay method of the 
DrugSite server.81  
 
3.3. Results 
 
3.3.1 Initial screening using DSF 
DSF was used for the initial screening of about 1000 compounds from a Maybridge Ro3 
diversity library. Compounds that shifted the Tm greater than ± 2 °C were selected for 
subsequent characterization by macromolecular crystallography. ± 2 °C was selected as 
the cutoff to afford a 2% hit rate that was desirable for follow-up. Screening allowed 
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identification of a total number of 21 hits. Nine of these caused upward (stabilizing) Tm 
shifts while the other twelve caused downward (destabilizing) Tm shifts (Table 3.1).  
 
3.3.2 Binding validation and characterization by X-ray crystallography 
An effort was made to obtain complex structures of BioA protein with all 21 fragment-hits 
identified with DSF with BioA protein. In order to evaluate all 21 compounds rapidly, 
soaking experiments were performed initially, using compound concentration of 5 mM in 
reservoir solution with 5-60 minute soak time. By this method, complex structures of 
fragments 2, 3, 5, 7, and 10 were obtained (Table 3.2). Further increases of the 
compound concentration to 10 mM did not result in additional complex structures. Later, 
co-crystallization methods were also applied to all 21 compounds, and one more 
complex structure (F9) was obtained (Table 3.2). Individual crystalline specimens 
diffracted to varying resolution, but data collection and refinement statistics show that all 
structures are well-refined and of good quality (Table 3.2). Among the fragment hits that 
are complexed with BioA in crystal structures, F2, 3, 5, 7, 9 are stabilizing hits (they 
increase BioA Tm) while F10 is a destabilizing hit (it decreases BioA Tm) (Figure 3.1).  
 
All fragment compounds bind in a hydrophobic pocket adjacent to the PLP cofactor but 
do not disrupt the internal aldimine that defines the resting state of the enzyme. Electron 
densities (Figure 3.2) clearly confirm that the covalent bond between Lys283 and the 
PLP in all complexes remains intact. 
  
The active site of Mtb BioA is composed of residues Pro24-Ser34, Ser62-Ala67, Arg156-
Asp160, His171-Arg181, Gln224-Gly228, Arg400-Arg403, Met87ʹ′-His97ʹ′, and Ala307ʹ′-
Asn322ʹ′ (See Chapter II). (Residues marked with a prime are contributed by the other 
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monomer of the functional dimer).  The shape of this active site is as a tunnel towards 
the inside PLP co-factor. This tunnel is at the interface of the two chains of the BioA 
homodimer; it is narrow inside but the opening to the surface slightly opens wider. The 
inner part of this tunnel is the substrate-binding site composed of Ala226, Trp65, Tyr157, 
Thr318ʹ′, Tyr25 and Asp160; the outer section of the tunnel is composed of hydrophobic 
loops from both chains (His171-Arg181, Ala307ʹ′-Met314ʹ′, Arg400-Arg403, Met87ʹ′-
His97ʹ′). All six fragments bind in the same portion of this active site occupied by KAPA in 
the pre-reaction complex (Figure 3.3), although they make different interactions with the 
surrounding residues. As previously discussed, Mtb BioA is a functional homodimer with 
two active sites. Fragments do not necessarily have the same binding features in both 
sites, and some fragments are found in only one of the active sites (Table 3.2).  There is 
no obvious difference between the chains that may readily explain this, but it is not 
unusual to see differences in binding of small molecules in the two “equivalent” positions 
in BioA crystals,21 even with respect to the covalent adduct that our group has previously 
described.25 More interestingly, the fragments have induced different local 
conformational changes in BioA. Some hydrophobic residues (aromatic side chains of 
Trp64, Trp65, Tyr25 and Phe402, for example) interact with fragments in different ways. 
Below is a structural analysis to highlight some useful information we obtained from each 
fragment structure. 
 
F2 
The co-crystal of F2 with BioA has a different crystal form (P21) from the other Mtb BioA 
structures (P212121); and there are two homodimers in one asymmetric unit (ASU). F2 
binds to only two active sites in one ASU (Chain A and Chain C), and in different 
orientations in the two sites.  As shown in Figure3.4A, they are flipped 180° “head to 
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tail”. In the A chain  F2 interacts with BioA active site mainly through nonspecific 
hydrophobic contacts; in chain C, F2 has H-bonds with the amide of Gly-93ʹ′ and with the 
backbone oxygen of Thr318ʹ′. The pyridine and thiophene rings of F2 are prone to favor 
a rigid co-planer conformation; F2 cannot form good π-π interactions with both Tyr-25 
and Trp64, and so binds so as to maximize the interaction with Trp-64 alone.  
 
F3  
F3 occupies both of the two BioA active sites in the asymmetric unit; however, in 
different binding conformations. When comparing the two binding modes, F3 is flipped 
180 o from one to the other, but the active site conformations remain the same (Figure 
3.4). F3 is structurally similar to F2; the imidazole and benzamide rings in this molecule 
are co-planar and they both participate in hydrophobic Van der Waals interactions with 
the aromatic residues of the Tyr25 and Trp64. When we compare the active site of F3 
complex structure to the BioA holo structure (pdb code 3TFT), we can see that a 30° 
shift in Tyr25 is induced to maximize the interaction with the imidazole (Figure 3.4. 
cyan), and Trp64 is rotated 90° to both make room for the binding and to have a better 
π-π interaction with the benzamide. The terminal amide group of F3 interacts with some 
surrounding water molecules but it does not form any hydrogen bonds directly with the 
surrounding residues; this fact also enables F3 to have different conformations in the 
BioA active site. 
 
F5 
The observed binding of F5 is comparable in both active sites of the asymmetric unit. F5 
is composed of a pyrazole ring, a phenyl ring and a terminal secondary amino group 
joined by rotationally flexible methylene linkers. The tetrahedral configuration of the 
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methylene carbon enables a 109° angle between the two planar aromatic systems and 
allows all elements of the molecule to be involved in specific interactions with the binding 
site. First, the pyrazole ring makes a π-π interaction with Phe402. The presence of F5 
caused a 0.9 Å inward shift of the Phe402 side chain to better accommodate this 
interaction. Second, the phenyl ring is in a hydrophobic pocket between Trp64 and 
Trp65. Trp64 is shifted 1 Å toward the fragment and the sidechain of Trp65 rotates 90o 
toward the fragment (comparing with the holo structure pdb code 3TFT) to make 
additional hydrophobic interactions. Finally, the secondary amine is 2.9 Å from the PLP 
phosphate oxygen where it donates a hydrogen bond to the PLP phosphate; it is also 
2.9 Å from the Tyr25 phenol oxygen to which it is hydrogen bonded. From a comparison 
of F5 to the complex with KAPA, we can see that the geometry of F5 allows it to occupy 
much the same binding footprint as KAPA even though these two molecules are 
structurally very different (Figure 3.3 C). 
 
F7 
F7 is observed bound in both active sites in the asymmetric unit. It occupies a sub-site 
adjacent to the binding site of F3. The saturated piperidine can be differentiated from the 
aromatic benzene ring because the electron density for the piperidine clearly shows the 
puckered chair conformation. The benzene ring of F7 resides in a hydrophobic sub-site 
between Phe402, Tyr407, Trp64 and Trp65. The ketone linking the benzene ring and the 
piperidine ring serves as a hydrogen bond acceptor paired with the indole NH of Trp65, 
although the geometry of this interaction is not ideal. The secondary amine in the 
piperidine is a hydrogen bond donor as it is protonated at neutral pH; it is involved in 
hydrogen bond interactions with Tyr157, Tyr25 and the PLP phosphate oxygen. No 
significant conformational changes to the BioA active site occur upon binding F7. 
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F9  
The binding of F9 was only observed in crystals prepared by co-crystallization, and it is 
only observed in one active site of the asymmetric unit. The main interaction it makes is 
a π-π interaction with Trp64. As in complexes with fragments 2 and 3, the Trp64 side 
chain is rotated approximately 90° to enable this binding conformation and to make this 
interaction. The lactone is twisted at a 45° angle from the core aromatic ring plane, 
enabling it to make a stacking interaction with Tyr25. 
 
F10  
F10 occupies only one of the two BioA active sites in the asymmetric unit. An 
unambiguous binding pose can be assigned due to higher density of the sulfur density 
on the thiazole ring.  F10 binds in direct contact with the PLP, oriented so that the amino 
group is hydrogen bonded to the phosphate of PLP, Tyr25 OH, Tyr157 OH and Gly316ʹ′ 
O (Figure 3.2 F). This terminal amine acts as a hydrogen donor to the PLP and the 
Gly316ʹ′ O; the third amine hydrogen is directed at the midpoint between the two 
hydroxyls of Tyr25 and Tyr157 to make a single bifurcated H-bond, much like those that 
sometimes occur to the midpoint of two carboxylate oxygens. The Tyr25 hydroxyl is also 
a weak hydrogen bond donor to the nitrogen in the thiazole ring of F10. The amino group 
of KAPA in the complex described in Chapter II makes these same interactions. The 
binding of F10 is accommodated with little change to the holo enzyme conformational 
state. The benzothiazole heterocycle lies aside the Lys283 side chain, and between the 
side chains of Trp64 and Trp65. The two tryptophan indoles are oriented with a 90° 
angle between them, and the benzothiazole plane almost perfectly bisects that angle, so 
that comparable hydrophobic contacts are made with each tryptophan. The 
benzothiazole is just long enough to stretch across the binding pocket and to pack at 
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right angles against the face of the aromatic ring of Phe402. Hydrophobic contacts also 
exist with Met174 and Ala226. 
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Figure 3.1. DSF results for F2, F3, F5, F7, F9, and F10. 
 
A: DSF melting curve amplification results. B: DSF melting curve derivative results. 
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Table 3.1. Fragment hits from DSF 
Fragment  
Id 
Maybridge 
Code 
Structure M. W. 
(Da) 
DSF 
Tm shift 
(°C) 
DSF 
ΔTm shift 
(°C) 
 
F1 
 
CC43209 
 
 
188.23 
 
90 
 
+5 
 
F2 
 
KM03152 
 
 
204.25 
 
90 
 
+5 
 
F3 
 
CC18528 
 
 
187.20 
 
89 
 
+4 
 
F4 
 
CC20809  
 
112.13 
 
89 
 
+4 
 
F5 
 
CC56046 
 
 
201.27 
 
89 
 
+4 
 
F6 
 
CC24118  
 
193.27 
 
88 
 
+3 
 
F7 
 
SEW04290  
 
189.25 
 
88 
 
+3 
 
F8 
 
SPB02598 
 
 
223.31 
 
88 
 
+3 
 
F9 
 
TL00757 
 
 
189.21 
 
88 
 
+3 
 
F10 
 
CC06013  
 
164.23 
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F11 
 
CC01313  
 
165.19 
 
76 
 
-9 
 
F12 
 
BTB08555 
 
 
200.24 
 
73 
 
-12 
 
F13 
 
CC55813 
 
 
233.35 
 
73 
 
-12 
 
F14 
 
AC10403  
 
115.18 
 
72 
 
-13 
 
F15 
 
CC58513  
 
213.28 
 
72 
 
-13 
 
F16 
 
CC04501 
 
 
173.17 
 
71 
 
-14 
 
F17 
 
MO01157 
 
 
204.31 
 
70 
 
-15 
 
F18 
 
CC30113  
 
176.26 
 
69 
 
-16 
 
F19 
 
MO01158 
 
 
218.34 
 
68 
 
-17 
 
F20 
 
TL00917  
 
155.62 
 
68 
 
-17 
 
F21 
 
BTB08015 
 
 
222.19 
 
65 
 
-20 
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Table 3.2. Crystallographic statistics for complexes with fragments 2, 3, 5, 7, 9 and 
10 
Data collection F2 F3 F5 F7 F9 F10 
PDB code 4WYA 4WYC 4WYD 4WYE 4WYF 4CXR 
Detector Saturn 944+ 
CCD 
DECTRIS 
PILATUS 6M 
DECTRIS 
PILATUS 6M 
DECTRIS 
PILATUS 6M 
DECTRIS 
PILATUS 6M 
DECTRIS 
PILATUS 6M 
Wavelength (Å) 1.541 1.000 1.000 1.000 1.000 1.000 
Space group P21 P212121 P212121 P212121 P212121 P212121 
Cell dimensions       
a, b, c (Å) 62.80, 
65.96, 
196.79 
63.29, 65.98, 
204.00 
63.10, 66.49,  
204.65 
62.69, 66.25, 
202.33 
63.09, 66.09, 
203.19 
62.94, 66.08,  
201.90 
α,β,γ (o) 90, 90.19, 
90 
90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 
Protein chains 
per ASU 
4 2 2 2 2 2 
Resolution (Å) 34.39-2.02 
(2.09-2.02) 
203.99-1.70 
(1.76-1.70) 
102.32-1.35 
(1.40-1.35) 
202.33 - 1.75 
(1.81-1.75) 
101.60-2.25 
(2.32-2.25) 
100.95-1.70 
(1.72-1.70) 
Rmerge 0.146 
(0.320) 
0.123 
(0.460) 
0.058 
(0.429) 
0.066 
(0.342) 
0.088 
(0.171) 
0.060 
(0.445) 
I/σI 4.1(1.1) 13.8 (3.2) 18.7 (4.1) 18.4 (4.3) 15.4 (10.3) 17.4 (3.8) 
Completeness 65.0% 
(7.8%) 
98.6% 
(94.4%) 
99.0% 
(99.2%) 
99.0% 
(99.2%) 
98.5%  
(96.7%) 
97.6% 
(96.2%) 
Multiplicity 1.9 (1.1) 6.4 (6.5) 6.4 (6.1) 6.0 (6.3) 4.9 (4.3) 4.4 (4.7) 
No. observations 135188 609249 1219705 516385 91412 381159 
No. unique 
reflections 
70447 94878 189301 85959 38797 86627 
       
Refinement F2 F3 F5 F7 F9 F10 
Resolution (Å) 29.9-2.50 39.7-1.70 32.8-1.35 39.4-1.75 101.6-2.25 100.9-1.70 
Rwork 
Rfree 
23.3 
31.0 
17.57 
21.34 
12.63 
15.54 
17.58 
20.62 
19.03 
23.56 
19.8 
22.6 
No. atoms 12665 7539 7811 7296 6787 6750 
No. water 49 779 937 546 206 232 
No. ligand 
molecule 
2 1 2 2 1 1 
No. PLP molecule 2 2 2 2 2 2 
No. other 
molecule 
0 0 2 0 0 3 
Ramachandran 
plot 
      
Favored 89.5% 96.6% 97.0% 96.6% 95.2% 96.6% 
Allowed 8.6% 2.9% 2.3% 2.7% 2.8% 2.7% 
Disallowed 1.9% 0.6% 0.7% 0.8% 2.0% 0.7% 
R.m.s deviations 
from ideality 
  
Bond lengths (Å) 0.010 0.007 0.006 0.007 0.009 0.008 
Bond angles (°) 1.36 1.17 1.14 1.16 1.32 1.32 
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Figure 3.2. Fragments in BioA active site with 2Fo-Fc (1σ) electron density display. 
A: F2, B: F3, C: F5, D: F7, E: F9, F: F10 
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Figure 3.3. Fragment structures overlaid on KAPA (shown in grey) to emphasize 
sidechain conformational differences induced by different ligands. A: F2; B: F3; C: 
F5; D: F7; E: F9; F: F10. 
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Figure 3.4. (A) F2 binding conformations in BioA active site. The binding 
conformation in chain A is shown in green and that in chain C is shown in cyan. (B) F3 
binding conformations in BioA active site. The binding conformation in chain A is 
shown in green and that in chain B is shown in cyan. 
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3.3.3 Assessment of fragment binding affinities  
DSF is a qualitative screening tool for hit identification; it provides evidence of inhibitor 
binding, but cannot provide quantitative assessments of ligand binding affinity. Likewise, 
X-ray crystallography provides detail regarding ligand binding; however, it has been 
shown that some weak binders (KD of 10-2M) can be characterized in a complex X-ray 
crystal structure.89 One piece of important information we cannot obtain from DSF or X-
ray crystallography is the fragment binding affinity. Fragments usually have 
comparatively low binding affinities to protein targets (as we discussed in Chapter 1); 
however, choosing a fragment with comparatively strong and specific binding as a 
starting point is crucial for accelerating future inhibitor design. For this reason, several 
different biophysical methods were explored for the purpose of determining the binding 
affinities of the fragments. 
 
STD-NMR was first used in attempt to determine the binding affinities of the fragments. 
As data collection for this experiment consumes a large amount of protein and 
compound samples, we only chose F10 to develop experience with this method. F10 
has three pairs of 1HNMR signal with chemical shifts at 4.54ppm, 7.43ppm and 7.95ppm 
respectively (Figure 3.5 a). We can identify their signal from the STD-NMR experiment 
(Figure 3.5 c). Proton signals in all of these 3 groups were used to calculate a KD value, 
but KD values estimated using different proton signals do not agree with each other. The 
KD was calculated as 17.2 µM from 1HNMR signal with chemical shifts at 4.54 ppm, 4.56 
mM from 1HNMR signal with chemical shifts at 7.43 ppm, and 58.8 mM from 1HNMR 
signal with chemical shifts at 7.95ppm. We turned to other methods to quantify the KD. 
The possible reason for the disagreement is further addressed in the discussion section. 
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SPR was our second option to estimate KD values. BioA was immobilized on a CM5 
Biacore chip using procedures described in section 3.2.3. Different concentrations of 
fragment compounds (31.25µM, 62.5µM, 125µM, 500µM, 1mM and 2mM) were flowed 
through the BioA surface channel and relative responses (RR) were collected for each 
experiment. A 1:1(Langmuir) binding model was used to fit the data and calculate the KD 
values. The compounds were not well-behaved in the SPR experiments and the KD 
values estimated from repeated experiments did not agree well.    
   
Isothermal titration calorimetry (ITC) was not chosen to be our primary fragment 
screening tool because it requires relatively large amounts of protein and ligand for each 
experiment. A big advantage of ITC is that it provides the thermodynamic parameters of 
protein-fragment interactions in solution. We have optimized the experimental conditions 
and realized that for the fragment hits, a relatively high protein concentration (0.1 mM) is 
necessary to achieve a high signal-to-noise ratio. Because of the high concentration 
(0.1mM) of BioA required in ITC experiments with low affinity fragment compounds, ITC 
experiments were only completed for the six fragment compounds confirmed to bind 
crystallographically. Three different fragment concentrations were used (1 mM, 1.5 mM, 
and 2 mM) (Figure 3.6), and all experiments were completed in duplicate with good 
reproducibility. The data with the best fitting curves were used to generate the 
thermodynamic binding parameters ΔH, ΔG, -TΔS, and KD summarized in Table 3.3.  
 
The ITC results showed that all six fragments have single or double-digit micromolar 
binding affinities, which is a good starting point for drug discovery. Taking into account 
the fact that the fragments are relatively small molecules, ligand efficiency (LE) was 
calculated for each fragment. All of fragments have good ligand efficiency (LE > 0.4). In 
particular, F10 has ligand efficiency as high as 0.59, showing high potential for 
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optimization into lead compounds. Calculated solvent partition coefficients often parallel 
small molecule binding in hydrophobic pockets, so calculated logarithm partition 
coefficients (cLogP) are included in Table 3.3.    
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Figure 3.5. STD-NMR spectra for F10. (a) is the reference 1H spectrum; (b) is the 
STD-NMR 1H spectrum; (c) is the difference spectrum which shows the ligand signal 
which confirmed that F10 binds.  
 
 
 
  
4.55.05.56.06.57.07.58.0 ppm
0 .
0 8
0 .
2 1
0 .
2 2
4.55.05.56.06.57.07.58.0 ppm
4.55.05.56.06.57.07.58.0 ppm
0 .
1 7
1 .
1 7
1 .
0 0
[L]=0.2 mM Tsat = 4 s
I0
Isat
(I0−Isat)
N
S NH2
03E03
H
H
H
H
H
H
7.9 
7.4 
4.5 
(a) 
(b) 
(c) 
  67 
 
Figure 3.6. ITC results for fragments 2 (A), 3 (B), 5 (C), 7 (D), 9 (E), and 10 (F) 
represented as a function of heat exchanged per injection.  
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The upper figures show the time dependence of the electric power (µcal/sec) to maintain 
constant temperature of the sample after each injection. The lower figures show the heat 
per mole of injectant vs. the molar ratio of the ligands and protein in the system. Figures 
from left to right are for each compound using 1mM, 1.5mM and 2M compounds.  
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 Table 3.3. Thermodynamic parameters of fragment binding with BioA 
 F2 F3 F5 
Structure 
 
 
 
ΔH,  
kcal mol-1 
-5.4±0.08 -6.1±0.15 -13.5±0.30 
KA, 
104M-1 
13.1±1.0 6.9±0.5 8.5±0.5 
ΔG,  
kcal mol-1 
-6.9 -6.6 -6.7 
-TΔS,  
kcal mol-1 
-1.5 -0.5 6.8 
KD,  
(µM) 
7.6 
 
14.6 
 
11.8 
 
cLogP 
 
0.7 1.3 1.6 
No. H 
bonds with 
BioA 
0 1 3 
Ligand  
efficiency* 
0.53 0.47 0.45 
  
F7 
 
F9 
 
F10 
Structure 
 
 
 
ΔH,  
kcal mol-1 
-4.2±0.35 -3.1±0.16 -1.3±0.07 
KA, 
104M-1 
2.3±0.3 4.6±0.6 5.9±0.7 
ΔG,  
kcal mol-1 
-5.9 -6.3 -6.5 
-TΔS,  
kcal mol-1 
-1.7 -3.2 -5.2 
KD,  
(µM) 
43.4 
 
21.6 
 
16.9 
 
cLogP 
 
1.2 1.2 1.0 
No. H 
bonds with 
BioA 
2 1 4 
Ligand  
efficiency* 
0.42 0.45 0.59 
 
*Ligand efficiency was calculated using the equation LE = (ΔG)/N where N is the number 
of non-hydrogen atoms in the molecule. 
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3.4 Discussion   
3.4.1 Difficulties in fragment binding affinity determinations 
Fragments are often weak binders; the binding affinity of fragments, especially in the 
form of ligand efficiency, is a very important piece of information that can help guide 
molecular designs based on fragments. STD-NMR, SPR and ITC are all biophysical 
techniques that can theoretically determine the binding affinities of low affinity ligands. 
However, in any particular case, any one of these techniques may prove unreliable. In 
the case of BioA, both STD-NMR and SPR experiments failed to provide valid and 
reproducible KD values.  In STD-NMR, the saturation transfer difference signal is not the 
same for protons with different chemical shifts. The distance of the fragment-associated 
proton to the protein is another factor: the closer the proton is to the protein, the stronger 
a STD signal will be. This feature can provide useful information regarding ligand 
binding. However, it has been argued that protons with larger STD-AFs will give rise to a 
higher apparent KD 87. In the case of BioA, using different proton signals results in 
different apparent KD values.  
 
SPR been used extensively to study fragment binding65–67,89. In the initial design of this 
experiment, we first used common amine coupling to immobilize BioA on the reflective 
chip. It is likely, however, that reagents used in the amine coupling interfere with the PLP 
cofactor binding in the BioA active site. To be more specific, the ethanolamine used to 
block the remaining exposed active carboxylates on the surface has potential to react 
with the aldehyde of the PLP, releasing it from the protein active site. Similarly, some 
fragment or inhibitor analogs may contain chemical groups that potentially react with 
PLP.  Irreversible modification of the protein or the surface to which it binds will impair 
data quality, since the quality of the protein surface cannot be restored between multiple 
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runs. For these reasons, we decided that SPR was not a suitable assay for determining 
our fragment binding affinities in this case.   
 
Isothermal titration calorimetry (ITC) is a biophysical technique often used to obtain 
thermodynamic parameters of ligand binding. It can be sensitive within the range 
required for analyzing fragment binding, and, when experiments are carefully conducted, 
it can produce robust outcomes. We have tested all of our fragments in replicate 
experiments with different ligand-protein ratios. KD values estimated using different 
conditions agree quite well, but there tends to be broader distributions of enthalpic 
energy (ΔH) and entropic energy (-TΔS) in the total energy when using lower 
ligand:protein ratios. This is due to the relative weakness of the fragment binding, as well 
as low molecular weight of the fragment ligands, which resulted in relatively low signal to 
noise ratios. Still, from the ITC results, we can quantitatively analyze if the fragment 
binding is enthalpy or entropy driven with reasonable reliability. This piece of information 
may be very important for later inhibitor design.  
 
3.4.2 Thermodynamics parameters of fragment binding  
Both enthalpic and entropic energies contribute to protein-ligand binding. Polar 
interactions with the “hot spots” (structurally conserved spots that are enriched in polar 
residues and can form strong hydrogen bonds with multiple ligands)90 are enthalpic 
contributions. Specific stabilizing non-polar interactions, such as those arising from π-π 
or π-proton interactions are also enthalpic contributions. Solvation of hydrophobic 
ligands and apolar binding pockets account for most entropic contributions. Most of 
these fragments have similar calculated logPs near 1.0, which suggests that little change 
in the entropy of solvation occurs when fragments bind.  A primary difference in the TΔS 
component of binding may arise in cases where conformational states achievable by 
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rotatable bonds in solution are excluded from binding to the BioA binding site.  Such 
restrictions would be reflected in an entropic penalty evident in thermodynamic data. 
 
Because fragments are small molecules (less than 22 heavy atoms), and few rotatable 
bonds, merely entropic energy of solvation (1kJ/mol per heavy atom) is not sufficient to 
drive binding. Enthalpy driven energies, such as hydrogen bonding interactions with hot 
spots (over 5 kJ/mol per H bond) and π-π interactions (1 kJ/mol per atom) contribute 
significantly to good fragment binding hits. The enthalpy favored binding relies largely on 
specific hydrogen bond interactions with the hot spots, that are unique features of the 
binding site. Thus, molecules with enthalpy driven binding are in general superior to 
entropy driven hits as “good starting points” in drug discovery91.  
 
ITC analysis enables us to quantify enthalpic (ΔH) and entropic (-TΔS) contributions to 
the total binding energy (Figure 3.7). From the thermodynamic parameters, most of the 
fragments have moderately favorable entropic interactions with BioA active site (-TΔS 
around -3, Figure 3.7).  The LogPs calculated for all fragments are similar and slightly 
greater than 1, from which we may surmise that they have similar entropies of solvation 
and a slight preference for a hydrophobic binding site. F5, however, is unique in the 
large unfavorable entropy upon binding to BioA (-TΔS 6.8, Figure 3.7). Compared to F5, 
fragments 2, 3, 7, 9 and 10 are more rigid compounds without rotatable linkers; their 
binding results in little net entropy change, F5 has more rotatable bonds and it can be 
more flexible in a solvent environment than in the binding pocket; the conformational 
constraints imposed upon binding result in a fairly large entropic penalty. This disfavored 
entropy is more than offset, however, by very favorable enthalpic energy of binding by 
this fragment. F5 makes 3 strong hydrogen bonds with a hot spot composed of the PLP 
O, Tyr25 O and Gly316ʹ′O. F7 and F10 also have more than 2 hydrogen bonds with 
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residues in BioA active site, but because the polar interactions are not in optimum 
geometries, enthalpic interactions with BioA appear to be weaker (Table 3.3). From our 
analysis of the ITC-derived thermodynamic parameters, we can characterize F5 as an 
enthalpy driven fragment hit, while the other fragments are enthalpy-entropy driven 
(Figure 3.7). Given the recommendation that preference be given to enthalpy driven 
binding91 F5 appears to be a better starting point than the other fragments for further 
molecular design. 
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Figure 3.7. Histogram of thermodynamic parameters of the fragment bindings 
A 
 
B 
 
A: Histogram of the ΔH (blue), ΔG(red) and -TΔS(green). Negative values shows energy 
favorable for binding. B: Plot analyzing the enthalpic and entropic component of the 
binding energy. The binding of F5 (yellow) is enthalpy driven, and the other fragments 
are enthalpy-entropy driven. 
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3.4.3 BioA active site conformational changes upon fragment binding 
 These structural results reveal that the BioA active site can adopt different 
conformations to accommodate binding and improve interactions with particular small 
molecules. In other words, upon binding with different non-covalent fragment ligands, 
different BioA binding site conformations were induced. How these conformational 
changes induced from the holo BioA state correlate with inhibition becomes an 
interesting question. In the study of the BioA complex structure with KAPA bound in its 
pre-catalytic site (described in detail in Chapter II), we observed no reorganization of the 
key residues that interact with fragments (Y25, W64, W65). These residues are believed 
to remain in the same conformation throughout the catalytic cycle. Key active site side 
chains occupy different combinations of conformations in different fragment complexes, 
as summarized in Table 3.4 and Figure 3.8. Interestingly, in six fragment complexes, the 
same configuration of these few sidechains is only observed twice.  F10 binds and 
induces no changes from the holo structure. Fragments 3 and 9 induce the same altered 
state. Some conformational attribute of each of the other complexes is unique. 
 
These versatile conformational adaptations would make BioA a challenging target for 
design of inhibitors based solely on the holo crystal structure. Computer-assisted 
methods such as molecular mechanics (MM) or molecular dynamics (MD), largely rely 
on assumptions that the protein conformation is unchanged upon ligand binding.  The 
fragment bound BioA structures sampled as a part of this study represent many possible 
conformations of the BioA active site.  Each should be considered as a possible bound 
state in future computational docking, scoring, or virtual screening. It will be important to 
match the ligand to the appropriate protein conformation, so that all specific interactions 
may be modeled accurately.  
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Table 3.4. Conformation clustering for key residues in the fragment-binding site.  
  Y25 W64 W65 F402 
BioA holo 0 and +30 0 0 0 
F2 0 -90 0 0 
F3 +30 -90 0 0 
F5 0 0 +90 0 
F7 0 0 0 0 and +45 
F9 +30 -90 0 0 
F10 0 and +30 0 0 0 
Side chain conformation of holo BioA (pdb-id 3TFT) was defined as position 0. 
Conformational changes of residues in each fragment complex structure is defined by its 
shifting angle and shifting direction (clockwise ‘+’ or counterclockwise ‘-‘).  
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Figure 3.8. Side chain conformations of key residues in BioA fragment binding 
sites showing in different colors.  
 
 
Cyan: BioA holo; Purple: F2 complex; Magenta: F3 complex; Yellow: F5 complex; 
Orange: F7 complex; Pink: F9 complex; Green: F10 complex. KAPA (grey) is included 
as a ligand binding position reference. 
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3.5 Conclusion 
In this chapter, we described a three stage protocol for fragment screening. From the 
initial DSF screen, 21 out of 1000 compounds were selected (hit rate 2.1%). Further 
validation using X-ray crystallography confirmed that 6 out of the 21 DSF hits bind in the 
active site of BioA (hit rate 0.6%). No other binding sites for fragments were found. 
Efforts have been made using multiple biophysical methods to obtain binding affinities of 
the 6 fragment hits and ITC provided such information. The binding of each fragment 
has been characterized structurally and specific molecular features have been identified 
that help to explain the origin of binding affinity for BioA.  This survey of multiple ligand 
bound complexes also has exposed considerable flexibility in the BioA active site that 
should be of use in interpreting future affinity data as the design of more potent and 
selective BioA inhibitors progresses. 
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Chapter IV: Structure-based Optimization of Fragment Binding 
 
Acknowledgement: Some material included in this chapter is excerpted from previously 
published work [ Dai, R. et al, 2014. "Inhibition of Mycobacterium tuberculosis 
Transaminase BioA by Aryl Hydrazines and Hydrazides ". ChemBioChem. 15(4):575-
586]. This includes portions of sections 4.2.5, 4.2.7, 4.2.8, 4.3.4, 4.4.1, 4.4.2 and figures 
4.6, 4.7 and 4.8. Ran Dai and Prof. Barry Finzel contributed equally in writing this 
published work, with assistance from other authors. Prof Courtney Aldrich contributed to 
part of the writing of section 4.4.1 and 4.4.2. Permission to use this copywrited material 
has been granted by John Wiley & Sons. The kinetic assays of F10-1, F10-2 and F10-3 
were done by Daniel Wilson from the lab of Prof. Courtney Aldrich. The ITC experiment 
of F5-1 was done by Dr. Feng Liu. 
. 
4.1 Introduction 
After the initial fragment screening, there are several options for lead optimization that 
we have discussed extensively in Chapter I. Fragment extension (or fragment evolution) 
is ideally applicable when a fragment shown to bind in one site of the target can be 
evolved by extension to make additional favorable interactions in an adjacent sub-site for 
more favorable binding (Figure 4.1) 35. Using this strategy, new chemical entities are 
designed based on the structural information of fragment binding to exploit additional or 
improved interactions with the existing binding site. There are many examples involving 
a variety of targets where a fragment extension strategy has been employed. 31,91-92  
 
Traditional SAR studies have been widely used in conjugation with fragment based 
approaches,93-94 but with the detailed fragment binding information from X-ray 
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crystallography, molecular designs can be much more rational. From the Mtb BioA 
structures we can see that all the fragments occupy portions of the active site near the 
PLP cofactor. This active site is a deep, tunnel-like pocket composed of loops 
contributed by both molecules of the homodimer including Pro24-Ser34, Ser62-Ala67, 
Arg156-Asp160, His171-Arg181, Gln224-Gly228, Arg400-Arg403, Met87ʹ′-His97ʹ′, and 
Ala307ʹ′-Asn322ʹ′ (Figure 4.2) 21. None of the fragments fill this site completely, so there 
are plenty of sub-sites adjacent to the fragments for extension. The high-resolution 
fragment complex X-ray structures reveal details of the BioA side chain conformations, 
and have allowed us to identify specific protein-ligand interactions that can be improved.  
 
The Maybridge Ro3 core library we used for fragment screening was composed of a 
relatively small number of molecules meant to be representative of a diverse chemical 
space; many analogs of these molecules are also commercially available. Often, even 
very small changes to fragment molecules can result in large improvements in potency 
and ligand efficiency33,95, so the purchase and characterization of available fragment 
analogs was undertaken as an efficient and economical method for initial fragment 
optimization, and to explore Structure Activity Relationships. Such “SAR by commerce” 
can provide a means to modify fragment hits at different locations with very tentative 
changes, but without expensive chemical synthesis.  
 
In this chapter, we report our discovery of Mtb BioA inhibitors a using structure-based 
fragment extension strategy. First the fragment bound structures were studied to identify 
opportunities for fragment extension consistent with binding position. Second, SAR by 
commerce was conducted to identify molecules with higher binding affinity and to 
explore SAR. In selecting compounds for purchase, both a “rule of 5” filter and structure-
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based filters were applied. Finally, the binding of selected compounds was evaluated by 
DSF and, when co-crystals could be prepared, X-Ray crystallography. Confirmed lead 
compounds were further characterized by biochemical activity or ITC.  
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Figure 4.1.  Fragment optimization by fragment extension.  
 
 
(A) Fragment hit as bound in a sub-site; (B) lead compound designed to extend into a 
neighboring sub-site (fragment extension).  Figure adapted from Rees et al. 35 
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4.2. Experimental Procedures 
 
4.2.1. Compound sources  
Compounds used in this chapter are purchased from Chembridge online chemical store 
(Hit2Lead.com) or requested from National Cancer Institute Developmental Therapeutics 
Program (NCI DTP). All chemicals used meet the high quality standard of 100% NMR 
identification. Compounds from Hit2Lead.com were at least 95% pure as evaluated by 
LC-MS and the compounds from NCI DTP were at least 90% pure by LC-MS.  
Compound IDs provided in Table 4.1 and 4.2 are Chembridge catalog IDs or NCI DTP 
compound IDs.   
 
4.2.2. Selecting analogs of fragment structures  
A substructure search method was used to identify commercially available analogs that 
contain core structural features of each fragment hit. The fragment core structures were 
selected based on the X-ray complex structures. They maintain the shape, 
hydrophobicity and polarity features of the original fragments; they are assumed to bind 
in the BioA active site in the same conformation as the original fragment hits. Scifinder 
and PubChem database servers were used to search for candidate compounds. 
Substructure searching was used to identify fragment analogs from extension. The core 
structures (shown in red in Table 4.1) were used to search molecules containing each 
core. In addition, a similarity search was used to identify other simple modifications that 
might potentially increase binding affinity. Only commercially available compounds were 
selected from the search results to build the initial candidate library for further screening. 
 
4.2.3. Filtering prospective analogs  
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50 compounds (Table 4.1) selected from Scifinder and PubChem databases were 
screened using the Lipinski’s Rule of 5 filter in the Schrödinger Suite. To do this, 
structures of the candidate molecules were input in Schrödinger software, a Ligprep was 
performed with Lipinski’s rule selected as the pre-filter. All the 50 small compounds 
passed through the Lipinski’s rule filter. Then 3D compound structures were built using 
the Prodrug Server96, and each compound was superimposed onto the fragment in the 
BioA binding site to align the conserved substructure to that in the X-ray structure so that 
molecules that introduce obvious steric conflicts could be eliminated. 
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Table 4.1. Compounds selected for initial SAR by commerce. The fragment core in 
each compound is colored red.  
Compound 
ID 
 Structure Template Descriptions 
10896690 
 
F3 
 
M.W. : 264 
H donor: 1 
H acceptor: 3 
cLogP: 1.24 
13846515 
 
F3 
 
M.W.  238 
H donor: 1 
H acceptor: 3 
cLogP: 1.22 
94450964 
 
 
F3 
 
M.W.  281 
H donor: 1 
H acceptor: 3 
cLogP: 2.70 
81034737 
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M.W.  251 
H donor: 1 
H acceptor: 2 
cLogP: 2.66 
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68302890 
 
 
F3 
 
M.W.  244 
H donor: 1 
H acceptor: 2 
cLogP: 2.14 
8895561 
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M.W.  222 
H donor: 1 
H acceptor: 2 
cLogP: 1.91 
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8902266 
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F5 
 
M.W.  301 
H donor: 2 
H acceptor: 4 
cLogP: 0.47 
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cLogP: 2.18 
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8925662 
 
 
F5 
 
M.W.  223 
H donor: 1 
H acceptor: 1 
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F10 
 
M.W.  204 
H donor: 1 
H acceptor: 1 
cLogP: 3.38 
5149753 
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M.W.  165 
H donor: 1 
H acceptor: 2 
cLogP: 1.04 
5107839 
 
 
F10 
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cLogP: 1.81 
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5107833 
 
F10 
 
M.W.  178 
H donor: 1 
H acceptor: 1 
cLogP: 2.76 
6060366 
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M.W.  259 
H donor: 1 
H acceptor: 1 
cLogP: 1.12 
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H donor: 1 
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cLogP: 1.5 
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H donor: 2 
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cLogP: 2.8 
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cLogP: 1.8 
S
N
NH2
N
S NH2
N
S
NH2
N
S NH2
N
H
N
N
N
O
N N
NH2
O
N
H
N
N
N
O
N N
NH2
O
NH
N
N
H2N
O
N N
NH2
O
  90 
 
NSC82637 
 
F3 
 
M.W. 244.68 
H donor: 0 
H acceptor: 3 
cLogP: 3 
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M.W. 226.23 
H donor: 1 
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cLogP: 1.5 
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cLogP: 1.3 
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H donor: 1 
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cLogP: 1.6 
NSC100127 
 
F3 M.W. 293.15 
H donor: 0 
H acceptor: 3 
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NSC87695 
 
F3 
 
M.W. 365.82 
H donor: 2 
H acceptor: 5 
cLogP: 3.8 
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NSC51515 
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M.W.  237.73 
H donor: 0 
H acceptor: 2 
cLogP: 2.7 
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NSC132804 
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M.W.  282.17 
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cLogP: 2.8 
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4.2.4. DSF  
The ability of fragment analogs (Table 4.1) to shift the BioA Tm was determined using the 
same experimental procedures for DSF as described for fragment screening (Section 
3.2.1).  The protein and ligand concentration used were the same.  
 
4.2.5. Crystallography.  
The crystallization conditions used to produce BioA crystals were as described in 
Chapter III (Section 3.2.5.). The diffraction data for the compounds F10-1, F10-2, and 
F5-1 were collected at 100 K using synchrotron radiation with a Dectris Pilatus 6M Pixel 
Detector on beamline 17-ID (IMCA-CAT) at APS, Chicago, United States. The data were 
processed, integrated, and scaled with XDS and SCALA78 using the autoPROC scripts 
available at IMCA-CAT. Data for a compound F10-3 co-crystal were collected at 100 K 
using Cu Kα radiation on a Rigaku HighFlux HomeLab rotating-anode system with a 
Saturn 944+ CDD detector in the Kahlert Structural Biology Laboratory at the University 
of Minnesota. This data was processed, integrated and scaled with d*TREK111. The data 
collection and processing statistics are given in Table 4.3. The structures were solved by 
molecular replacement as described in Chapter III (Section 3.2.5). 
 
4.2.6. ITC  
The ITC experimental procedure for compound F5-1 was as described in Chapter III 
(Section 3.2.4). ITC experiments were performed by Dr. Feng Liu in the lab of Prof. 
Courtney Aldrich. 
 
4.2.7. UV-Vis spectroscopy  
A NanoDrop 1000 UV–Vis spectrophotometer (Thermo Scientific) was used for all UV–
Vis spectroscopy. Mtb BioA protein (2.0 µL, 0.16 mM) in HEPES (25 mM, pH 7.5), NaCl 
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(50 mM, 1 mM EDTA), TCEP (0.1 mM) was mixed with compound F10-1 (2.0 µL, 0.4 
mM) in HEPES (25 mM, pH 7.5), NaCl (50 mM), EDTA (1 mM), TCEP (0.1 mM) and its 
UV-Vis spectrum was immediately measured upon mixing. UV-Vis spectra were taken at 
0 s, 15 s, 30 s, 60 s and 120 s after mixing. 
 
4.2.8. Steady-state Kinetics  
Mode of inhibition studies were carried out under initial velocity conditions in a total 
volume of 50 µL at 25 °C in 384 well black plates (Corning 3575).  Reactions were set 
up in triplicate and consisted of BioA (114 nM) in reaction buffer (100 mM Bicine pH 8.6, 
50 mM NaHCO3, 1 mM MgCl2, 0.0025% Igepal CA-630, 5 mM ATP, 0.1 mM PLP, 320 
nM E. coli BioD, 20 nM Fl-DTB, 184 nM streptavidin, and 1 mM TCEP) with either 
variable amounts of KAPA (0.94–7.5 µM) with SAM (2.34 mM) or with a variable amount 
of SAM (0.3–2.5 mM) with a fixed amount of KAPA (1.9 µM).  Each substrate 
concentration was run with 0, 31.25, 62.5, and 125 µM inhibitor.  Reactions were 
monitored on a microplate reader using an excitation of 485 nm, and emission at 535 
nm.  A standard curve of dethiobiotin (2.7 nM–2 µM) in reaction conditions lacking only 
BioA was used to convert fluorescence into enzyme velocities as previously described73.  
The data was fit using the enzyme kinetics module of SigmaPlot to competitive, 
uncompetitive, and non-competitive models and the model with the highest r2 value was 
selected. The PLP utilizing enzymes alanine transaminase (ALT, EC 2.6.1.2) and 
aspartate transaminase (AST, EC 2.6.1.1) were used to test off target inhibition of F10-1.  
Reactions were carried out in 100 µL in 96 well UV clear half-area plates (Corning 3679).  
For ALT, reactions consisted of enzyme (10 mU) in reaction buffer (60 mM Bicine pH 
8.0, 0.1 mM NADH, 1 mM TCEP) containing 100 mU lactate dehydrogenase (LDH) and 
either fixed α-ketoglutarate (75 µM) with 0.625–10 mM alanine or fixed alanine (10 mM) 
with 6.25–50 µM α-ketoglutarate.  Each concentration of substrate was run with DMSO 
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or 29.6–66.7 µM F10-1. The reactions (in duplicate) were monitored by the decrease in 
A340 that corresponds to the consumption of NADH by LDH upon the formation of 
pyruvate from ALT.  Initial velocities were calculated using the molar absorptivity of 
NADH  (6220 M-1 cm-1 at 340 nm) and fit as described above using SigmaPlot.  To test 
for inhibition of AST 2 mU of enzyme in reaction buffer containing 100 mU malate 
dehydrogenase (MDH), 236 µM α-ketoglutarate and 0.156–2.5 mM aspartate was tested 
against F10-1 (100 µM). The kinetic assay was done by Mr. Daniel Wilson in the lab of 
Prof. Courtney Aldrich.  
 
4.3 Results 
4.3.1. Substructure search, similarity search and structure based virtual screening  
50 commercially available compounds were selected to build the initial library from 
fragment optimization. These 50 compounds all passed through the Lipinski Rule of 5 
filter. We superimposed these optimized compounds in the fragment position in the 3D 
complex structures. By excluding molecules that had steric conflicts with the binding 
pocket, the number of compounds for purchase was reduced to 16 (Table 4.2). 
 
4.3.2. DSF and X-ray crystallography of compounds from commerce  
DSF was used to measure the Tm shifts of BioA upon binding with the 16 purchased 
compounds. Detailed Tm shifts are listed in Table 4.2. Nine out of sixteen compounds 
induced a Tm shift equal or greater than ± 2 °C. We used both soaking and co-
crystallization to try to obtain complex X-ray structures. Co-crystallization techniques 
resulted in better crystal quality and higher ligand occupancy than the soaking method. 
As an additive to the reservoir solution, the adduct-forming compounds increased the 
rate of complex crystal growth. The co-crystals have potential to diffract to beyond 1.3 Å 
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as we observed in data collection. Complex structures were obtained for 2 of the 16 
compounds purchased. These are identified as F10-1 and F5-1, (Figure 4.2). 
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Table 4.2 Biophysical Characterization Of Compounds From Commerce. 
The fragment core structures maintained in the designed compounds are colored red. 
Cmpd ID     Structure DSF 
Tm(oC) 
ΔTm 
(oC) 
Fragment 
Template 
X-ray data 
 
 
5107833 
  
 
83 
 
-2 F10  
F10-1 
5108103 
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83 -2 F10  
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83 -2 F10  
5767021 
 
 
83 -2 F10  
 
6060366 
 
 
73 -12 F10  
F5-1 
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74 -11 F5 Complex 
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Figure 4.2 Acquired fragment analogs yielding new crystallographic complexes.  
  
The fragment core structures maintained in the designed compounds are colored red. 
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4.3.3. F5 optimization 
Compound F5-1 was selected because from the F5 complex structure it appeared that 
replacing the terminal secondary amine with a primary amine would result in more 
favorable configuration for hydrogen bonding interactions with the PLP phosphate 
oxygen and the Tyr25 hydroxyl group (Figure 4.2). F5 induced a stabilizing shift of four 
degrees (Tm = 89 °C), while compound F5-1 induced a destabilizing shift of eleven 
degrees (Tm = 74 °C) (Figure 4.2).  
 
The crystal structure of the complex with F5-1 has been determined at 1.62 Å resolution 
(Table 4.3) and is illustrated in Figure 4.3A. The compound binds in the same site as F5 
and in a very similar conformation (Figure 4.3). The conformations of the key residues 
(Y25, W64, W65, F402) in BioA active site are also the same as the F5 complex. F5-1 
differs in two respects from F5. First, F5-1 has a terminal primary amine while F5 has a 
secondary amine. The primary amine has a more favorable electronic configuration to 
form hydrogen bonding interactions with both PLP phosphate oxygen and Tyr25 
hydroxyl group. On the other hand however, the secondary amine has the terminal 
methyl group as an electron pushing group that should make the secondary amine a 
stronger electron donor in the H bonding. With this analog, we were interested to see if 
the terminal methyl group is necessary for the fragment binding, and found that it is not 
crucial. Compound F5-1 also includes a chloride substituent on the pyrazole ring not 
present on the parent fragment.  The electron density for the ligand in the F5-1 complex 
shows that the pyrazole chloride can exist in at least three different conformations that 
arise from alternate rotations of the pyrazole ring about the linking bond.  The nitrogen 
atoms in the pyrazole ring make no specific hydrogen bonding interactions with the 
surrounding residues that might make one conformation more favorable than another. 
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The key BioA amino acid residues in the binding site retain the same conformations as 
observed in the complex with F5.        
 
ITC was used to characterize the binding affinity of compound F5-1. The KD value is 
7.5µM (Figure 4.4A), which is modestly (1.7 fold) better than the KD of F5 (12.5 µM) 
(Figure 4.4B). This result agrees with our structure observation from X-ray 
crystallography. The modification of the secondary amine to a primary amine maintained 
similar strength of the hydrogen bonding interactions; F5 has a ΔH of binding of −13.7 
kcal/mol while F5-1 has a ΔH of −11.4kcal/mol (Figure 4.4).  
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Figure 4.3. A comparison of BioA complexes with Compounds F5-1 and F5. 
 
(A) Complex with compound F5-1, and  (B) with F5. 1σ 2Fo-Fc electron density for the 
ligand, Lys383, and the PLP is shown for each complex  (mesh). 
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Figure 4.4 ITC results for F5 and its optimized analog F5-1. 
 
ITC results for (A) F5, and (B) F5-1. The upper figures show the time dependence of the 
electric power (µcal/sec) to maintain constant temperature of the sample after each 
injection. The lower figures show the heat per mole of injectant vs. the molar ratio of the 
ligands and protein in the system.  
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4.3.4. Discovery of a reversible covalent inhibitor from F10 optimization 
Compound F10-1 was selected as a promising analog because from the F10 complex 
structure it appeared that a nitrogen in the place of the F10 α-carbon could provide an 
extra hydrogen bonding interaction with Thr318ʹ′ hydroxyl group. This compound induced 
an even larger destabilizing Tm shift of nineteen degrees (Tm = 67 °C) (Figure 4.2). It did 
not escape our attention that this is nearly the Tm assigned to apo BioA.74 
As crystal soaking experiments were begun with Compound F10-1, it became clear that 
this analog behaves differently in the presence of BioA. The PLP-bound holo enzyme 
crystals typically grown under the same conditions are yellowish in color.25 Holo BioA 
crystals change color from yellow to red within 2 minutes when placed in the F10-1 
soaking solution (Figure 4.5). In co-crystallization experiments, a similar phenomenon 
was observed. Within seconds of the addition of Compound F10-1 to crystallization 
drops, the solution develops a deep red color suggestive of chemical reaction. The 
reaction of F10-1 with BioA can be followed spectroscopically, with the time-dependent 
increase in absorbance at 330 and 500 nm and a decrease at 420 nm that suggests the 
reaction is complete in just a few minutes (Figure 4.5). Co-crystals of the complex were 
prepared under the same conditions as holo crystals, but the red color clearly 
concentrates in the crystals. Diffraction data for Compound F10-1 co-crystals were 
collected to 1.90 Å resolution (Table 4.3). 
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The crystal structure of the complex with F10-1 is shown in Figure 4.6. The hydrazine 
analog forms a covalent adduct with the PLP aldehyde to form an extended cis-azo 
quinonoid species. The bond between PLP and Lys283 is clearly broken, and the lysine 
amino group is relocated to H-bond with Thr318ʹ′.  This was clearly not the case with 
bound fragment F10, where the bond between Lys-283 and the PLP is intact (Figure 3.2. 
F). A planar Schiff base is formed with the hydrazine, and the entire benzothiazole is 
well-defined in unambiguous electron density (Figure 4.6A).  While the benzothiazole 
can still be said to occupy the SAM binding subsite, it is rotated ~90° from the position 
occupied by its template, F10, shifted significantly away from Tyr 25, and out of direct 
contact with Phe402 (Figure 4.6A). Two localized enzyme conformational adjustments 
involving only the reorientation of side chains occur in conjunction with adduct formation. 
The hydroxyl group of Tyr 407 shifts 2.5 Å from the holo enzyme position to make a new 
H-bond to the carbonyl oxygen of Arg400. If unchanged, a short contact to benzothiazole 
C7 would have existed. In the largest conformational change, the side chain of Trp65 
rotates from the holo position (chi1=-60°; chi2=-20°) to a new position (chi1=-60°; 
chi2=90°) so that the hydrogen on the indole Nε1 is positioned for optimal interaction 
with the benzothiazole π system. Tyr25 occupies two different positions in this complex 
with roughly equal occupancy.  In one conformation, the OH is H-bonded to Asp160 and 
the OH of Tyr157 as in the holo structure.  In the other, the side chain is rotated so that 
the OH makes an H-bond with the alternate carboxylate oxygen of Asp-160 (Figure 
4.6A). 
 
To determine whether or not the inhibition of BioA by Compound F10-1 is reversible, the 
BioA–Compound F10-1 adduct was dialyzed, which resulted in loss of the deep red color 
and full restoration of the enzyme activity. To further characterize the modality of 
inhibition, steady-state kinetic studies were performed under initial velocity conditions. 
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Double reciprocal plots of initial reaction velocity under conditions with varying inhibitor 
and reactant concentration (Figure 4.7A) show that Compound F10-1 is a competitive 
reversible inhibitor of BioA with respect to SAM, (Ki = 10.4 ± 0.6 µM), and an 
uncompetitive inhibitor with respect to KAPA (Kiu = 85.4 ± 3.4 µM).  This is the expected 
behavior for an inhibitor of one step of a ping pong bi-bi mechanism97. In forming a 
reversible adduct with the PLP cofactor, Compound F10-1 inhibits the same BioA 
enzyme form (PLP-BioA) with which SAM reacts. The inhibition pattern against KAPA is 
uncompetitive, because KAPA binding is required to regenerate the PLP-bound form of 
BioA.  
 
In an effort to explore whether Compound F10-1 possesses any selectivity, it was 
evaluated as an inhibitor of alanine transaminase (ALT), and of aspartate transaminase 
(AST), two other important mammalian PLP-dependent transaminases98.  Mode of 
inhibition studies reveal that Compound F10-1 is an uncompetitive reversible inhibitor of 
ALT with respect to α-ketoglutarate with a Kiu value of 74.0  ± 8.2 µM and a competitive 
inhibitor with respect to alanine (Ki = 18.9 ± 1.6 µM) (Figure 4.7B).  As with BioA, the 
inhibitor competes for binding with the compound that is the amino group donor 
responsible for converting the BioA protein from PLP bound holo form to the 
pyridoxamine phosphate (PMP) state. We did not observe any detectable inhibition of 
AST, however (data not shown).  While Compound F10-1 may not be a selective 
inhibitor of BioA, it is also not entirely non-specific.   
 
Armed with the knowledge that Compound F10-1 is a reversible competitive inhibitor of 
BioA, we chose to investigate attributes of the analogous hydrazide (Compound F10-2; 
Figure 4.2).  Compound F10-2 also gave rise to a large destabilizing Tm shift (-15 °C; 
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Figure 4.2). We were also able to characterize the complex by co-crystallization (Table 
4.3). No visible color change is observed upon addition of F10-2 to BioA. 
The crystal structure of Compound F10-2 also confirms the formation of a covalent 
adduct, but again, the bound adduct conformation is unique (Figure 4.6B). From high 
resolution diffraction data (1.7 Å resolution) we can assert that conjugation throughout 
the Schiff base appears complete; each of the atoms is sp2-hybridized and planar in its 
bonding, but there is a subtle curvature imposed throughout the adduct that likely implies 
some degree of electronic strain. While the side chain of Trp65 remains primarily in the 
rotated position required to accommodate the adduct with F10-1, the benzothiazole in 
the complex with F10-2 is positioned well above and out of contact with it, but stacks 
instead against the indole of Trp64. F10-2 induces a side chain configuration similar to 
that induced by F7 (Chapter III Table 3.4 ), except that Y25 adopted the conformation in 
F3 complex. The hydrazide carbonyl is oriented toward the Trp65 indole nitrogen, but it 
is 3.9 Å away from it – too far to be considered a stabilizing hydrogen bond. A water-
mediated interaction is possible, but no well-ordered water molecule is observed. The 
benzothiazole also does not point directly toward Phe402, but instead reaches past it 
and into the larger pocket bounded by Arg400, the side chain that interacts directly with 
the carboxylate of KAPA. Tyr25 is observed in the same two conformations found in the 
complex with F10-1. 
 
The structural similarity between Compound F10-2 and isoniazid (Compound F10-3 in 
Figure 4.2), one of several chemical agents that comprise the cocktail of drugs often 
used to treat Mtb infections, led us to evaluate this aryl hydrazide as a BioA inhibitor.  In 
the same battery of biophysical studies, isoniazid appears to interact with BioA.  It 
produces a more modest but still large negative shift in the Tm (-8 °C), and 
crystallographic analysis shows that it forms a covalent adduct with the PLP that is very 
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similar to that formed by compound F10-2 (Figure 4.6C). Nevertheless, in the coupled 
BioA assay used to assess inhibition kinetics73, both hydrazides F10-2 and F10-3 show 
no inhibitory activity toward BioA (Ki > 100 mM).   We are led to conclude that these 
adducts seen crystallographically are so easily reversed upon exposure to substrates 
that no significant amount of competitive inhibition can be observed by these low affinity 
compounds.  
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Table 4.3 Collection and refinement statistics of the optimized compounds F5-1, 
F10-1, F10-2 and F10-3 
Ligand ID F5-1 F10-1 F10-2 F10-3 
Isoniazid 
PDB id 4WYG 4MQP 4MQQ 4MQR 
Data collection 
site 
IMCAT IMCAT IMCAT in house 
Detector DECTRIS PILATUS 
6M 
DECTRIS PILATUS 
6M 
DECTRIS PILATUS 6M Saturn 944+ CCD 
Wavelength (Å) 1.000 1.000 1.000 1.541 
Space group P212121 P212121 P212121 P212121 
Cell dimensions     
a, b, c (Å) 63.12, 66.43, 205.32 63.02, 65.92, 201.96 62.95, 66.35, 203.97 63.13, 66.48, 203.68 
α,β,γ (°) 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 
molecules per 
ASU 
2 2 2 2 
Resolution (Å) 205.32-1.62 
(1.625-1.62) 
201.96-1.83 
(1.93-1.93) 
63.05-1.55 
(1.555-1.55) 
63.20-2.10 
(2.18-2.10) 
Rmerge 0.058(0.190) 0.063(0.284) 0.088(0.366) 0.055(0.182) 
I/σI 22.3(8.7) 18.0(5.5) 14.0(2.7) 16.6(2.8) 
Completeness 96.2%(94.7%) 98.3%(96.6%) 99.0%(86.0%) 88.4%(73.4%) 
Multiplicity 6.8(6.4) 6.4/6.3 6.2/4.5 3.22(2.17) 
No. observations 725282 467939 757129 145139 
No. unique 
reflections 
106327 73075 121718 45088 
     
Refinement     
Resolution (Å) 46.40-1.62 100.93-1.83 101.99-1.70 101.84-2.10 
Rwork/Rfree 15.2/18.0 17.8/20.8 17.6/20.4 20.7/25.5 
No. atoms 7951 7106 7597 6885 
No. water 879 474 747 375 
No. ligand 
molecule 
2 2* 2* 2* 
No. PLP 
molecule 
2 2 2 2 
No. other 
molecule 
11 4 4 4 
Ramachandran 
plot 
    
Favored 706 (96.4%) 758 (95.0%) 707 (96.7%) 784 (94.0%) 
Allowed 22(2.9%) 27(3.4%) 20(2.7%) 35 (4.2%) 
Disallowed 5(0.6%) 13(1.6%) 4(0.6%) 15 (1.8%) 
R.m.s deviations     
Bond lengths (Å) 0.008 0.009 0.009 0.01 
Bond angles (°) 1.15 1.34 1.27 1.31 
* PLP molecules are in adduct form with ligands in the structure.   
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Figure 4.5. Colorimetric Characterization of F10-1 binding. 
 
A-D: Time-lapsed photos of a PLP-bound BioA crystal soaked in Compound F10-1 (15% 
PEG 8000, 100 mM HEPES pH 7.5, 100 mM MgCl2, and 5 mM Compound F10-1) over 2 
minutes. E: UV-Vis spectroscopy of 0.16 mM PLP bound BioA (Holo BioA) upon mixing 
with 0.4 mM Compound F10-1 at different time points.  
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Figure 4.6. Crystal Structures of analogs of F10. 
 
A-C) A comparison of complexes of covalent adducts created by reaction of PLP with 
Compounds F10-1, F10-2, and F10-3. Covalent adducts are labeled PLP-F10-1, PLP-
F10-2, and PLP-F10-3, respectively. 1σ 2Fo-Fc electron density for Lys383, the PLP and 
each ligand is shown (mesh).  Electron density clearly shows that the bond to Lys283 is 
replaced with a covalent bond to each compound. Tyr25 is shown in two conformations 
when so observed. Local binding environment of each adduct (F10-1-F10-3) is shown in 
the same orientation in frames D-F) to emphasize structural similarities and differences.  
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Figure 4.7 Inhibition studies with Compound F10-1 
 
Initial rate data of variable amounts of inhibitor and either KAPA (A) or SAM (B).  KAPA 
was varied from 0.94 to 7.5 µM and SAM was varied from 0.3–2.5 mM with the fixed 
substrates held at 2.34 mM for SAM and 1.9 µM for KAPA.  F10.1 was used at 
concentrations of 0 µM (●), 31.3 µM (○), 62.5 µM (▼), 125 µM (▽).  The inhibitor is 
uncompetitive with respect to KAPA and competitive with respect to SAM with Ki values 
of 85.4 ± 3.4 µM and 10.4 ± 0.6 µM respectively. Inhibition of ALT by F10.1.  C)-D): 
Initial rate data of variable amounts of inhibitor with respect to α-ketoglutarate (C) or 
alanine (D).   The substrate α-ketoglutarate was varied from 6.25 to 50 µM and alanine 
was varied from 0.625 to 10 mM with the fixed substrates held at 10 mM for alanine or 
75 µM for α-ketoglutarate.  Compound 2 was used at concentrations of 0 µM (●), 29.6 
µM (○), 44.4 µM (▼), and 66.6 µM (▽).  The inhibitor is uncompetitive with respect to α-
ketoglutarate and competitive with respect to alanine with Ki values of 74.0 ± 8.2 µM and 
18.9 ± 1.6 µM, respectively. 
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4.4 Discussion 
 
4.4.1. Stabilization of an azo-quinonoid intermediate 
Compounds F10-1, F10-2 and F10-3 all react with the PLP co-factor reversibly to form 
stable covalent adducts.  The UV-Vis spectroscopy and crystallography results for 
Compound F10-1 confirm that the hydrazine analog forms an extensively conjugated cis-
azo-quinonoid species.  While similar quinonoids form transiently as intermediates in the 
catalytic mechanism of all transaminases, they are rarely captured.99 We propose a 
mechanism for the stabilization of this adduct from F10-1 in Figure 4.8A. By analogy to 
the reaction with substrates, the hydrazine first displaces the lysine to form a PLP-
coupled imine. Tautomerization of this imine leads to the formation of an azo-quinonoid; 
the delocalized bonding is responsible for the beautiful sanguine color. Further reversible 
tautomerization of the pyridoxal ring is possible through conjugation all the way to the 
benzothiophene (Figure 4.8B). This is a unique chemical feature of Compound F10-1 not 
shared with the hydrazides (F10-2 or F10-3) that can only form less extensively 
delocalized imines (Figure 4.8C). While these hydrazide adducts are evidently more 
stable than the PLP-lysine Schiff base that they supplant, the fact that these compounds 
show no detectable inhibition in competition with substrates suggests that their stability 
is low.  The hydrazine adduct, however, with a Ki of 10 µM is unusually stable, which is 
approximately 80-fold lower than the Km of SAM.72  
 
The reactivity of hydrazines and hydrazides with PLP dependent transaminases has 
been known for decades and the kinetics of inhibition were studied in detail long ago.100 
More recently, there have been a number of attempts to increase the potency of 
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inhibitors of PLP-dependent enzymes that contain a reactive hydrazide. Ejim et al. 
confirmed the formation of a stable adducts to PLP bound in cystathionine beta-lyase 
with a series of hydrazinocarbonylmethylbenzamides, and were able to improve inhibitor 
binding affinity by 50-fold with the preparation of small analog library.101 Another 
hydrazide has recently been identified as an inhibitor of E.coli BioA by whole-cell 
phenotypic screening.102 Others have investigated a series of aryl hydrazides as 
inhibitors of LL-diaminopimelate aminotransferase. Structure-activity relationships 
revealed in the study of these systems have identified the reactive hydrazide as a 
necessary, but not sufficient molecular feature needed for inhibition. Potent inhibition can 
only occur when other binding site complementarity also exists.  These examples do not 
benefit from the extensive electronic delocalization that occurs upon reaction with the 
hydrazylbenzothiophene of Compound F10-1. For this reason, we suggest that this 
compound may serve as a particularly effective starting point for further optimization. 
Whether selective inhibitors of BioA can be generated from the 2-(hydrazinyl)benzo-
thiophene lead remains to be determined, but the complexes with compounds 
characterized as part of this study have exposed a variety of different conformational 
states that are accessible to the BioA enzyme that should prove valuable in the 
structure-based design of more potent inhibitors based on this scaffold.   Our analysis of 
the hydrazides and hydrazines derived from optimization of F10 has been recently 
published62. 
 
4.4.2. The Value Of Destabilizing Fragment Hits 
Many of the studies evaluating the use of thermal shift methods for identification of 
protein ligands focus only on molecules that increase the transition temperature.82, 103-104 
All of the new compounds that were discussed in this chapter shift Tm significantly 
downward. This is true of the initial non-covalent template for F10-1, F10-2 and F10-3 
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(F10, ΔTm = -5 °C), as well as the reversible adducts with ΔTm shifts in the range of -6 to 
-16 °C. Although the template for Compound F5-1 (F5) induces an upward Tm shift (ΔTm 
= 4 °C), F5-1 has a ΔTm shift of -11 oC. In prior DSF studies, we have tentatively 
ascribed a much lower Tm (67 °C) to the apo (PLP-free) form of BioA,74 and were initially 
drawn to these fragment hits because we expected to find that the molecules bound in 
place of the PLP. Structural characterization of these compounds clearly shows this is 
not the case. Why these compounds are so sharply destabilizing is not known; it may be 
that they play a greater role in the stabilization of the unfolded state. Empirically, it is 
useful to note for the benefit of those hoping to conduct similar studies with other 
proteins, that destabilizing compounds may also be worth structural investigation. 
Compounds that destabilize a protein are expected to lead to more rapid protein 
degradation. In Mtb, damaged proteins are removed by the Pup-proteasome system. 
Thus small molecules that lead to protein destabilization could potentially result in 
protein depletion, which may be advantageous under non-replicating conditions where 
protein synthesis is not occurring to replenish degraded proteins. 
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Figure 4.8. Mechanisms of covalent adducts of hydrazines and hydrazides 
 
A) Proposed mechanism of F10-1-PLP adduct formation; B) Tautomerization of F10-1-
PLP adduct; C) Proposed mechanism of F10-2-PLP adduct formation.      
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4.5. Conclusion 
 
 
In this chapter, we have described our work toward the structure-aided optimization of 
six BioA fragment hits. Commercial based SAR and binding structure based virtual 
screening allowed us to experimentally work on a manageable number of purchased 
compounds. We have identified 4 ligands that can be co-crystallized with BioA out of a 
total of 19 compounds we purchased; 2 of them were confirmed with improved binding 
affinity or inhibition (F5-1 and F10-1).  
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Chapter V: Fragment structure-based optimization of BioA HTS 
hits 
Acknowledgement: Sections 5.2.4-5.2.6, 5.3.2 first paragraph and figure 5.2 include 
excerpts from the work [S.W. Park, et al., "Target-Based Identification of Whole-Cell 
Active Inhibitors of Biotin Biosynthesis in Mycobacterium tuberculosis". Chem. Biol.In 
Press.]. Prof. Barry Finzel contributed the writing of section 5.3.2 first paragraph and 
making figure 5.2 (A-C). The ITC experiments in this section were performed by Dr. 
Feng Liu in the lab of Prof. Courtney Aldrich. 
 
5.1 Introduction 
 
Protein-fragment complex structures provide invaluable information for rational inhibitor 
design. As discussed in chapter I, three different strategies are often used in fragment 
based lead design. Fragment extension is used to grow a single fragment into adjacent 
sub-sites; and fragment linking can be applied when two fragments bind in two sub-sites 
and they can be tethered using a linker.  In the real world, however, there may be 
multiple fragments or lead compounds that bind in the same site of the target but make 
different interactions105; when these bound compounds partially overlap with each other, 
fragment merging strategies can be used to optimize the lead compounds.  
Fragment merging strategies are not limited to fragments; the same approach can be 
used to optimize more potent lead compounds whenever diverse molecules share the 
same binding site. This strategic recombination of ligand molecular features has often 
been called “scaffold hopping”. It requires a structural understanding of how lead 
compounds bind to the targets from experimental or virtual models. It aims at 
interchanging core ligand structural features (the scaffold) of lead compounds in a way 
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that allows them to retain a predictable binding conformation and biological potency106. 
The purpose of the “hopping” to a different scaffold is to find novel active chemotypes 
that are also “drug-like”. Scaffold hopping is often used to optimize the pharmacokinetic 
properties of lead molecules (absorption, distribution, metabolism, and excretion, 
profiles), or to achieve improved selectivity toward the intended target.  
Scaffold hopping is routinely used to optimize lead compounds from HTS when 
structural knowledge of the binding of multiple compounds is known. Traditional scaffold 
hopping method includes heterocycle replacements, ring opening or closure, 
peptidomimetics, topology-based hopping and small-step hopping107. Virtual tools and 
computational models may be used to assist in design to reduce the high expense 
required to synthesize unpromising compounds108. Still, computational designs can be 
better supported if more experimental structural information is available. The beauty of a 
fragment merging strategy for optimization of HTS leads is that, by combining varied 
fragment binding features with known lead binding features, the effective number of 
scaffolds available for recombination attempts can be greatly expanded, thereby 
improving the likelihood that improved molecules can be designed. 
 
Recently Baeschlin et al. 109 described such an excellent example. In their work, 
structure information from fragment complex structures obtained using X-ray 
crystallography were combined with other structures to identify a higher affinity inhibitor 
of renin. In their research, an NMR-based screen was applied to a small focused library 
of 113 compounds against the aspartyl protease. Hit compound 1 (Figure 5.1) identified 
by fragment screening was crystallized with the target and its binding features were 
studied. In parallel, a HTS screening effort resulted in the discovery of lead compound 2 
(Figure 5.1). Crystallographic structures showed that the diphenylmethane moiety of 
compound 2 bound in a similar position as the tricycle of compound 1. Upon 
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incorporating the tricyclic framework into compound 2, they derived compound 3 with 
enhanced potency. Further optimization led to discovery of compound 4 with nanomolar 
potency (Figure 5.1).  
 
In parallel to our fragment-based lead discovery effort with BioA, the Aldrich laboratory in 
collaboration with D. Schnappinger has completed screening for functional inhibitors of 
biotin biosynthesis in Mtb20,73. In 2011, Dr. Courtney Aldrich’s group developed a 
continuous coupled assay and used this assay to screen a LOPAC library, resulting in 
the identification of several potent lead inhibitors73. Later, the Molecular Libraries and 
Small Molecules Repository (MLSMR) compound collection of more than 350,000 
compounds (PubChem AID#602481) was screened (in press; Chemistry & Biology). 
Also included were 83,000 compounds from the diversity-oriented synthesis (DOS) 
compound collection. To identify potent inhibitors, they first employed a novel 
fluorescence-displacement functional HTS assay. This novel assay was a modification of 
a continuous coupled assay they previously developed to meet the high throughput 
purpose. From this screening, about 7,600 hit compounds (hit rate 0.095%) with high 
diversity were identified. To select compounds with cell-based activity that specifically 
target the biotin biosynthesis pathway, a whole-cell counter-screen was performed in 
biotin-free and biotin-containing media with isogenic bioA Mtb strains that possess 
differential sensitivity to BioA inhibitors. This counterscreen successfully filtered out off-
target hits to allow identification of BioA-specific ligands active in a cellular context. By 
clustering similar compounds, a number of different inhibitor scaffolds with whole cell 
activity were identified.  
 
As structural biologists of this team, we determined X-ray crystal structures of BioA 
complexes with representatives of some of the most potent clusters of compounds from 
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this screening effort. With the structural analysis, it became clear that the HTS 
compounds bind in positions that partially overlap fragment binding sites already 
identified (Chapter 3). This fact allowed us to compare the complex structure of each 
HTS compound with each fragment complex structure and use fragment merging 
strategies to optimize the leads from HTS. 
 
In this chapter, we report the structural characterization of six HTS lead compounds in 
complex with BioA via X-ray crystallography. H01 through H05 are HTS lead compounds 
identified by the Mtb whole cell counterscreen; H08 is one promising lead compound 
from the miniature LOPAC screening 73. We then describe our effort to employ structure-
based lead optimization strategies that merge details of these complexes with 
information from  fragment hits described in Chapter 3.  
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Figure 5.1. Optimization of a renin inhibitor by fragment merging.109 
 
 
The fragment (Compound 1, shown in blue) was identified by NMR screening of a 
focused library. Compound 2 (red) is an HTS hit. Compound 3 was designed using the 
fragment merging method. The retained features of Compound 2 were shown in red and 
the modified feature from Compound 1 was shown in blue.  
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5.2 Experimental procedures 
 
5.2.1. Compound sources.  
The seven HTS compounds (H01-H08) were provided by our collaborator, Dr. Courtney 
Aldrich. H01-H07 are lead compounds from the MLSMR library; H08 is from the LOPAC 
library (Sigma-Aldrich). H03-1 and H03-2 were synthesized by Feng Liu in the lab of 
Prof. Courtney Aldrich. 
 
5.2.2. DSF  
The temperature of thermally induced unfolding Tm of high-affinity inhibitors were 
determined using Differential Scanning Fluorimetry procedures modified from those 
employed in fragment screening (section 3.2.1.); the ligand concentrations were 
adjusted because the HTS compounds have much higher affinities than the fragments. 
2475 µL of 2X master mix were made at room temperature by mixing 125.0 µL of 1M 
HEPES pH 7.5, 50.0 µL of 5M NaCl, 5.0 µL of 5000X Sypro orange stock solution, 2295 
µL of water. The 2X master mix was cooled on ice. 310 µL of water were distributed into 
each well of a single column of a 96-well U-bottom plate at room temperature. 19 µL of 
water were placed into each well of the white PCR plate held by a room-temperature 
aluminum block. 1 µL of pure DMSO was placed in each well of the first and last column 
for DMSO-only controls. Using a multi-channel P10 pipette, 1 µL of high affinity ligand 
(10mg/ml) was placed into a white PCR plate. BioA protein (25 µL of 13.0 A280) was 
added to the master mix. 310 µL of the 2500 µL 2X master mix was distributed into each 
well of a single column of a 96-well U-bottom plate on ice. 20 µL of master mix with 
protein was added into each well of the white PCR plate and gently mixed. Plates were 
sealed and run in the Bio-Rad CFX96 using 30 sec dwell time per 1°C temperature 
increase.  
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5.2.3. Crystallization  
BioA was co-crystallized with the HTS leads and the synthesized optimized compounds 
by the vapor diffusion method in a hanging drop at 20 °C. The crystallization procedure 
used is as described in Chapter 3 and Chapter 4, except the compound concentration in 
the initial drops was 0.25 mM. 
 
5.2.4. Data collection, processing and model building  
The diffraction data for H01 and H08 co-crystals were collected at 100 K using Cu Kα 
radiation on a Rigaku HighFlux HomeLab rotating-anode system with a Saturn 944+ 
CDD detector in the Kahlert Structural Biology Laboratory at the University of Minnesota. 
The diffraction data for H02 and H03 co-crystals were collected at 100 K with a NOIR-1 
CCD at the Advanced Light Source (Berkeley, CA). The diffraction data for H04, H05, 
H03-1 and H03-2 were collected at 100 K with a Dectris Pilatus 6M Pixel Array Detector 
on beamline 17-ID (IMCA-CAT) at the Advanced Photon Source, (Argonne, IL). The data 
for H01, H02, H03 and H08 were processed, integrated, and scaled with d*TREK111. The 
data for H04, H05, H03-1 and H03-2 were processed, integrated, and scaled with XDS76 
and SCALA88 using the autoPROC scripts available at APS-17-ID (IMCA-CAT). The 
structures were solved by molecular replacement using Phaser77  in the CCP4 package78 
using atomic coordinates from PDB code 3TFT as a search model25. Refinement and 
model building was done using Phenix112 and coot80. The figures were prepared with 
PyMOL (The PyMOL Molecular Graphics System, Version 1.5.0.4 Schrödinger, LLC.). 
 
5.2.5. 3D visualization of the binding models of designed compounds  
To analyze the binding features of the 6 HTS compounds and compare them with the 
fragment hits to design next generation compounds, structures were superimposed for 
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analysis and display using the shared BioA-PLP overlay method of the DrugSite 
server81. Three dimensional models of the designed compounds were built using 
Prodrug server110  and Jligand 113. Bound models of the designed compounds with BioA 
were built by putting the designed compounds into the electron density generated by 
their mother template molecules and regularizing the geometry and fit to density in coot. 
  
5.2.6. ITC.  
Isothermal Titration Calorimetry was conducted on a GE MicroCal Auto-ITC 200 
microcalorimeter. The titration experiment was performed at 25°C in ITC buffer (25 mM 
Hepes pH 7.5, and 50 mM NaCl). BioA was exchanged into ITC buffer using an Amicon 
Ultra concentrator, and the final enzyme concentration was determined using the 
Bradford assay. During the titration, 103 µM compound solution was injected into a 
solution of the enzyme containing 10.2 µM. The KA (the association constant in M-1), n 
(the number of binding sites per monomer) and ΔH (enthalpy) values were determined 
by ITC. The thermodynamic parameters (ΔG and –TΔS) were calculated using Equation 
1. 
 ∆G = −RTInk = ∆H− T∆S   (1) 
 
Where ΔG, ΔH and ΔS are the changes in free energy, enthalpy, and entropy of binding, 
respectively, R = 1.98 cal mol-1 K-1, and T is the absolute temperature. The affinities of 
compounds for BioA are provided as the dissociation constant (KD =1/KA). ITC 
measurements were performed by Dr. Feng Liu in Dr. Aldrich’s lab.  
 
5.3 Results 
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5.3.1. DSF and X-ray crystallography for the HTS lead compounds.  
DSF was used to measure the Tm shifts of BioA upon binding with the 7 HTS 
compounds in Table 5.1. Detailed Tm shifts are listed in Table 5.1. All 7 HTS compounds 
induced a positive Tm shift equal to or greater than 4 °C. The Tm shifts do not appear to 
correlate with the IC50 data from the continuous fluorescence displacement assay (Table 
5.1). Some very potent compounds are tabulated with IC50s below 8x10-8 M due to the 
limits in the sensitivity of the HTS assay. A DSF-derived Tm in not available for H08 
because this compound was not tested. 
 
We used co-crystallization to try to obtain complex X-ray structures in order to more 
thoroughly characterize inhibitor binding. Previous experience has shown that co-
crystallization results in higher diffraction resolution and higher ligand occupancy. Co-
crystallization of all eight compounds was attempted. We were able to obtain complex 
structures for six out of the eight. Complete electron density is observed for ligands H01-
H04; however for H05 that is a larger molecule, clear electron density is observed for 
only part of the molecule (Figure 5.2E). The electron density of the terminal 3-
methoxyaniline reflects only partial occupancy in the modeled conformation. The 
crystallographic statistics for all structures are listed in Table 5.2. 
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Table 5.1 Structures, DSF Tm shifts and BioA activity from HTS  
 
Cmpd ID Structure DSF Tm 
(°C) 
ΔTm 
(°C) 
BioA Activity 
IC50 (M) 
X-ray result 
H01 
 
BRD-
A72996250-
001-08-9 
 
 
 
93 
 
+8 
 
1.15x10-7 
 
Complex 
H02 
 
BRD-
K50105093-
001-06-6  
 
93 
 
+8 
 
< 8x10-8 
Complex 
H03 
 
BRD-
K19973577-
001-01-3  
 
94 
 
+9 
 
9.55x10-8 
Complex 
H04 
BRD-
K02445078-
001-10-6  
 
94 
 
+9 
 
< 8x10-8 
Complex 
H05 
 
BRD-
K57668161-
001-08-9  
 
90 
 
+5 
 
2.25x10-7 
Complex 
with partial 
ligand 
density 
H06 
 
BRD-
K32354586-
001-08-3 
 
 
 
91 
 
+6 
 
< 8x10-8 
 
H07 
 
BRD-
K93108830-
001-01-8 
 
 
89 
 
+4 
 
< 8x10-8 
 
H08 
 
CHM1 
 
   
4.44x10-7 
Complex 
N
S
O
O
O
F
O
O
O O
O
S
N
N
O
N
O
Cl
N
N
O
N
H
N
N
S
SO
O
N
HN
O
O
N+O
O-
OHO
S
N
O
N
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CF3
O
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N
H
N
O
O
O
F
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Table 5.2 Crystallographic Statistics for Complexes with HTS-derived Compounds 
Ligand	  name	   H01	   H02	   H03	   H04	   H05	   H08	  
Data	  collection	  site	   In	  house	   ALS	   ALS	   IMCAT	   IMCAT	   In	  house	  
Detector	   Saturn	  944+	  CCD	   NOIR-­‐1	  CCD	   NOIR-­‐1	  CCD	   Dectris	  Pilatus	  6M	   Dectris	  Pilatus	  6M	   Saturn	  944+	  CCD	  
Data	  set	  name	   	   	   	   	   	   	  
Wavelength	  (Å)	   1.541	   1.000	   1.000	   1.000	   1.000	   1.541	  
Space	  group	   P212121	   P212121	   P212121	   P212121	   P212121	   P212121	  
Cell	  dimensions	   	   	   	   	   	   	  
	  	  	  a	  (Å)	  
	  	  	  b	  (Å)	  
	  	  	  c	  (Å)	  
63.04	  	  66.24	  204.24	   63.08	  66.21	  204.44	   63.13	  66.04	  203.56	   63.29	  66.01	  203.63	   63.06	  66.05	  203.89	   62.755,	  66.153,	  203.261	  
α,β,γ	  (°)	   90,	  90,	  90	   90,	  90,	  90	   90,	  90,	  90	   90,	  90,	  90	   90,	  90,	  90	   90,	  90,	  90	  
molecules	  per	  ASU	   2	   2	   2	   2	   2	   2	  
Resolution	  (Å)	   102.1-­‐2.24	  (2.14-­‐2.24)	   63.08-­‐1.80	  (1.90-­‐1.80)	   47.33-­‐1.80	  (1.86-­‐1.80)	   203.6-­‐1.85	  (1.86-­‐1.85)	   102.0-­‐1.60	  (1.61-­‐1.60)	   101.6-­‐2.47	  (2.51-­‐2.46)	  
Rmerge	   0.089	  (0.471)	   0.076	  (0.560)	   0.098	  (0.529)	   0.100	  (0.392)	   0.058	  (0.347)	   0.084	  (0.083)	  
I/σI	   10.2	  (1.7)	   19.8	  (2.6)	   9.2	  (1.6)	   16.0	  (6.7)	   18.2(4.0)	   12.3(6.2)	  
Completeness	   96.1%	  (81.2%)	   90.5%	  (58.7%)	   96.8%	  (79.0%)	   99.8%	  (100%)	   	  100%	  	  	  (99.9%)	   94.08%	  (79.4%)	  
Multiplicity	   3.20	  (1.90)	   6.6	  (4.2)	   6.06	  (2.89)	   6.1	  (6.4)	   6.5(5.6)	   2.9	  (1.7)	  
No.	  observations	   133962	   477296	   468895	   450465	   733585	   81740	  
No.	  unique	  reflections	   41863	   72681	   77334	   73689	   113212	   28186	  
Mosaicity	   0.14	   0.12	   0.4	   0.11	   0.3	   0.5	  
	   	   	   	   	   	   	  
Refinement	   H01	   H02	   H03	   H04	   H06	   H08	  
	  	  	  Resolution	  (Å)	   28.19-­‐2.24	   102.0-­‐1.90	   47.33-­‐1.80	   101.82-­‐1.85	   101.94-­‐1.60	   101.63-­‐2.46	  
	  	  	  Rwork	  
	  	  	  Rfree	  
0.1768	  0.2086	   0.182	  0.221	   0.193	  0.223	   0.191	  0.213	   0.203	  0.220	   0.179	  0.220	  
	  	  	  No.	  atoms	   6938	   7422	   7138	   6891	   6870	   6821	  
	  	  	  No.	  water	   383	   738	   481	   357	   398	   212	  
	  	  	  No.	  ligand	  molecule	   2	   2	   2	   2	   2	   2	  
	  	  	  No.	  PLP	  molecule	   2	   2	   2	   2	   2	   2	  
	  	  	  No.	  other	  molecule	   6	   8	   3	   2	   0	   3	  
Ramachandran	  plot	  
	  	  	  Favored	   96.6%	   96.6%	   96.4%	   96.2%	   95.9%	   94.9%	  
	  	  	  Allowed	   2.7%	   2.4%	   3.0%	   3.2%	   3.0%	   3.5%	  
	  	  	  Disallowed	   0.7%	   1.0%	   0.6%	   0.6%	   1.1%	   1.6%	  
R.m.s	  deviations	   	   	   	   	   	   	  
	  	  	  Bond	  lengths	  (Å)	   0.003	   0.007	   0.007	   0.008	   0.006	   0.006	  
	  	  	  Bond	  angles	  (°)	   0.95	   1.26	   1.19	   1.21	   1.13	   1.06	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Figure 5.2 HTS Compound Omit Electron Density  
 
Crystal structures for the HTS compounds with 3σ omit density (Fo-Fc) from co-crystal 
structures of H01(A), H02(B), H03(C), H04(D), H05(E) and H08(F) (cyan), and the 
molecular environment surrounding the binding site near the PLP (Green).  Comparable 
binding is observed in both active sites of the BioA heterodimer, but only one is shown.  
Residues from one monomer (colored wheat) are identified with primes; those from the 
other (colored white) are not. 
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5.3.2. Structural characterization of the ligand binding   
Unambiguous electron density affirms that each inhibitor binds in the hydrophobic site 
adjacent to the PLP co-factor where substrate KAPA also binds62(Figure 5.2). This is 
also the same site into which fragment molecules bind.  Inhibitors are in contact with 
structural components of both monomers, distinguished by color in Figure 5.2. Each 
inhibitor induces shifts in the conformation of sidechains of Tyr25 and Trp64 to 
accommodate the longer, flatter molecules which lie sandwiched between repositioned 
aromatic rings of the tyrosine below and the tryptophan above.   
 
Interactions between the inhibitors and BioA are primarily hydrophobic and arise from 
two subsites. A subsite on the right (orientation defined by Figure 5.2) is formed by the 
juxtaposition of Pro24 and Trp 64 with residues 91ʹ′-93ʹ′ and 316ʹ′-318ʹ′ (primes denote 
residues of the other BioA monomer). A subsite on the left exists between the side chain 
of Tyr25, Tyr157 and the loop formed by Gly172-Met174. A detailed summary of 
observations regarding the binding of each compound follows. 
 
H01. (Figure 5.2A) The sulfoxide moity of H01 is in the hydrophobic sub-site composed 
of Tyr25, Tyr 157, Phe402, Trp64 and Arg403. The core pyrrole is tightly stacked 
between Tyr25 and Trp64. The Fluorobenzene attached to the pyrrole ring twists a 30o 
angle with the core and it is interacting with a hydrophobic subsite composed of Met91’, 
Gly93’, Gly316’ and Arg400. The fluorine is interacting with the hydrophobic Met91, and 
it can potentially form a fluorine hydrogen bond with the amide backbone of Gly93’. The 
sulfinyl oxygen is having hydrogen bonding with Tyr157, the phosphate oxygen of PLP 
and Asp160 bridged with a water molecule. However, the two esters did not make 
specific interactions. In the H01 complex, the conformation of the residues in the BioA 
active site resembles the conformation observed in F3 and F9 complexes.  
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H02. (Figure5.2B) H02 is composed of two aromatic systems: the core chromenone and 
the thiophene are linked by a carbonyl group. The thiophene resides in the hydrophobic 
subsite composed of Met91ʹ′, Gly93ʹ′, Gly316ʹ′ and Arg400, which the fluorobenzene of 
H01 interacts with. The core chromenone is stacked between Phe402 and Tyr25. The 
terminal diethylamine extends into a sub-site composed of Tyr157 and Gly172 
backbone. In the H02 complex, the conformation of the residues in the BioA active site 
resembles the conformation of the F3 and F9 complexes. 
 
H03. (Figure5.2C) H03 is a linear compound with three hydrophobic rings linked 
together. It occupies all three sub-sites that H02 interacts with. The left chloro-benzene 
ring is in the sub-site the diethylamine of H02 resides, which is composed of Gly172, 
Tyr157 and Cys168. The piperazine is in the middle sub-site composed of Tyr25 and 
Trp64. It has strong hydrophobic interaction with Tyr25. It also serves as a linker 
between the two aromatic rings. The acetophenyl ring on the right is making π-π 
interactions with Trp64. The carboxyl oxygen is a hydrogen bond acceptor that interacts 
with Glyʹ′93 backbone amide. In the H03 complex, the conformation of the residues in the 
BioA active site resembles the conformation seen in F3 and F9 complexes. 
 
H04. (Figure5.2D) H04 shares similar structural features with H03. It is also a linear 
combination of three hydrophobic rings; the linker moiety is also a piperazine with a 
carbonyl group. However, H04 is not binding in the same fashion as H03; it is 180o 
flipped from H03. There are two major differences between H03 and H04: the right hand 
side acetophenyl ring of H03 was replaced by a phenyl ring in H04, and the left hand 
side chlorophenyl was replaced by a benzothiadiazole. This flip enabled H04 to have 
  134 
 
more favorable interactions, because the right hand side sub-site(which is composed of 
Met91ʹ′, Gly93ʹ′, Gly316ʹ′ and Arg400) has a hydrogen bond donor(backbone amide of 
Gly93ʹ′), and the benzothiadiazole can have hydrogen bonds with Gly93ʹ′. In addition, the 
flipped binding conformation of H04 allowed its benzothiadiazole to accommodate a 
better Pi-Pi interaction with Trp64. One the other hand, the phenyl ring also extended 
deeply into the left sub-site which is composed of  Tyr157, Gly172’ and Gly156. In the 
H04 complex, the conformation of the residues in the BioA active site resembles the 
conformation seen in the F2 complex. 
 
H05. (Figure5.2E) H05 is composed of three hydrophobic ring systems. It has a four-
atom linker between the piperidine and the terminal phenyl ring, which adds more 
flexibility to this compound. The thiophene and the piperidine are interacting with the 
right hand side hydrophobic subsite of BioA in the similar fashion as H03 and H04: the 
right hand side carbonyl oxygen has a hydrogen bond with Glyʹ′93 backbone amide; the 
thiophene resides in the sub-site composed of Trp64 and Pro24, having π-π interactions 
with Trp64; the piperidine goes through a wide tunnel composed of Tyr157, Phe402 and 
Tyr25. The terminal methoxyphenyl ring is linked with the piperidine by a C4 linker. The 
density of the methoxyphenyl is not very complete. From the density model, we can see 
that, the terminal methoxyphenyl exists in two different conformations and potentially 
targets two different sub-sites. In one conformation, the methoxyphenyl resides in the 
sub-site composed of Gly172, Tyr157 and Cys168, which H03 and H04 also interact 
with. In another conformation, which is the major conformation, H05 methoxyphenyl 
extended into a sub-site composed of Tyr25, Met174 and Trp178. The methoxy oxygen 
makes a hydrogen bond with the indole of Trp178. In the H05 complex, the conformation 
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of the residues in the BioA active site resembles the conformation observed in the F3 
complex. 
  
H08. (Figure5.2F) H08 has very strong hydrophobic interactions with the hydrophobic 
sub-site composed of Trp64, Pro24, Tyr25 and Phe402. Trp64 and Tyr25 side chains 
make π-π interactions with the quinoline moiety and the fluorophenyl moiety of H08. The 
Tyr25 side chain is shifted about 1 Å towards the fluorophenyl ring and the phenyl plane 
is rotated through a 300 angle to accommodate the π-π interaction. The fluorine induces 
a 15o rotation angle between the two ring systems, which allows both rings to have π-π 
interaction with the surrounding residues. H08 also has a hydrogen bond with Glyʹ′93 
backbone amide. In the H05 complex, the conformation of the residues in the BioA 
active site resembles the conformation seen in the F2 complex.  
 
5.3.3. Optimization of the HTS compounds based on fragment merging-molecular design 
  
As the HTS compounds bind in the same subsite as the fragments bind, we were able to 
overlay the fragment structures and HTS compound structures to seek opportunities to 
combine features of two molecules to gain affinity and selectivity. However, as we 
overlay the structures one by one, we discovered that it is not easy to find components 
of different molecules that align well. This is not surprising. Protein conformational 
flexibility aggravates the unalignable vector problem, because the binding site actually 
drifts as large hydrophobic side chains in the binding site (Trp 64, Trp 65, Tyr 25, 
Phe402) change conformation. Despite of these facts, we were able to identify some 
possibilities for fragment merging. 
 
Optimization opportunities for H01:  
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Following an overlay of the H01 complex structure with the complex with F3, the 
hydrophobic cores of the two molecules align in the same spot; the angles between the 
two hydrophobic rings in the two molecules are also the same (Figure 5.3A). This 
comparison led to the suggestion that the core aromatic ring scaffold can be changed, 
Derivatives of H01 with altered aromatic rings in the hydrophobic core were designed 
(Figure 5.3A H01.1-H01.5).  
 
In overlaying complexes of H01 and H08, we observed that, although both compounds 
have a fluorobenzene ring, they do not overlap; instead, the H08 fluorobenzene ring 
overlaps with an ester in H01 (Figure 5.3B). Substitution of this H01 ester with an 
aromatic ring could potentially increase binding affinity by improving the π-π interaction 
with Y25 (Figure 5.3B H01.6, H01.7, H01.9). From modeling, we predict that the phenyl 
ring will adopt a good orientation for effective π-π stacking against Tyr25 (Figure 5.4B).  
The fluorobenzene of H01 interacts with the right hand side hydrophobic site in BioA.  
This is the same sub-site occupied by the dioxole in the complex with H08.  There is 
extra space in this sub-site that should permit the addition of a polar substituent (i.e., a 
carboxylate) to the para position of the benzene ring (Figure 5.3B H01.8, Figure 5.4C). 
Such a carboxylate should be positioned upon binding to form a specific hydrogen bond 
with the Glyʹ′93 backbone amide. From modeling, the distance between the carbonyl 
oxygen and the Glyʹ′93 backbone nitrogen is 3.1Å (Figure 5.4C), and the C-O-N angle 
was 81.10. The angle is not very favorable for the hydrogen bond; the flexibility of the 
binding site to accommodate this compound needs to be further tested.  
 
Optimization opportunities for H03: 
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Figure 5.5A illustrates the excellent coincidence of atoms in the complexes of HTS 
compound H03 and F9.   The overlap is good not only on the aromatic core, but also in 
the coincidence of polar atoms. Grafting a five-membered ring onto the H03 
acetylphenone would potentially strengthen the π-π  interaction relating this aromatic 
ring system to the Trp64 indole, as these two rings are already parallel with each other 
(figure 5.5A-C).  In addition, the carbon on the meta-position of the fluorobenzene ring is 
3.2 Å away from the hydroxyl oxygen of Tyr25 (Figure 5.5D). The Tyr25 hydroxyl can 
either be a hydrogen bond donor or acceptor. This carbon could be replaced with a 
heteroatom such as nitrogen or oxygen to gain an additional hydrogen bond (Figure 
5.5D).  
Compounds designed based on our structure-based and fragment-based approaches 
are being synthesized in the Aldrich laboratory. When synthesis is completed, analogs 
will be characterize by X-ray crystallography and bioassays and compared to design 
expectations. 
  
  138 
 
 
 
 
Figure 5.3 BioA inhibitor design by merging H01 with F3 or H08. 
    
A) H01 and F3 overlaid in the BioA active site, and corresponding designed inhibitor 
examples; B) H01 and H08 overlaid in the BioA active site, and corresponding designed 
inhibitor examples. 
 
  
  139 
 
Figure 5.4 Binding models of the designed compounds made using coot.  
 
A) BioA-H01 X-ray crystal structure; B) model of inhibitor designed from Merging 
features of H01 and H08 (H01.6); C) and D) model of inhibitor designed from H01 to 
gain an extra hydrogen bond with Glyʹ′93 backbone nitrogen (H01.8).    
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Figure 5.5 BioA inhibitor designs optimizing H03.  
 
A) Overlaid H03 and F9 complexes, and designed inhibitor conceptions; B) BioA-H01 X-
ray crystal structure; C) Model of compound designed by merging H03 with F9; D) 
Rationale for changing the meta carbon on the fluorobenzene to a heteroatom.  
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5.3.4. Synthesis and characterization of the optimized compounds from HTS.  
 
Independently, collaborators in Aldrich lab have performed  more general scaffold 
hopping, and made a variety of analogs of the most potent HTS leads. Compounds H03-
1 (Figure 5.6B) and H03-2 (Figure 5.6C) are two of such analogs synthesized by Feng 
Liu in the Aldrich lab. These two compounds have been characterized by X-ray 
crystallography (Figure 5.6E and F) and ITC experiments. H03-1 and H03-2 structures 
were both obtained by co-crystallization. Co-crystals with H03-1 and H03-2 diffracted to 
resolutions of 1.5 Å and 1.6 Å respectively; X-Ray data collection and refinement 
statistics show that these structures are well-refined (Table 5.3).  
 
The bound conformation of H03-1 is the same as that found with the original HTS 
template H03. The cyclopentanone ring added in place of the acetylphenyl group makes 
an extended hydrophobic interaction with the aromatic Trp64 side chain as predicted 
(Figure 5.6E, H). Encouragingly, this crystallographic structure closely resembles the 
predicted binding conformation for one of our designed cyclopentadienone inhibitors 
(Figure 5.5C). From the ITC experiment, we observed a 3-fold decrease of KD value 
(654 nM for H03 vs. 211 nM for H03-1) (Table 5.4). 
   
H03-2 was designed by using a benzodioxole ring to take place of the fluorobenzene 
ring of H03 (Figure 5.6C). From the X-ray structure, we can see that the orientation of 
the molecule in the active site remained the same as H03, however, the conformation of 
the piperazine ring changed from a chair to a twist (Figure 5.6G, I, J). The oxygen on the 
carbonyl group which links the piperazine ring and the fluorobenzene ring shifted 
towards Phe402 by 1.7 Å and the benzene ring also rotated 15o due to the conformation 
change. Phe402 Phenyl ring rotated 450 to make room for these changes. 
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Figure 5.6 X-ray crystallography structures of H03, H03-1 and H03-2.  
 
A-C) Structures of H03, H03-1 and H03-2; D-F) co-crystal structures of H03, H03-1 and 
H03-2 with 3σ omit density (Fo-Fc) maps; G-I) co-crystal structures of H03, H03-1 and 
H03-2 in a different view; J) An overlaid view of H03 (G) and H03-2 (I) in BioA active 
site. 
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Table 5.3 Crystallographic statistics for complex structures of H03-1 and H03-2 
Ligand name H03-1 H03-2 
Data collection site IMCAT IMCAT 
Detector Dectris Pilatus 6M Dectris Pilatus 6M 
Wavelength (Å) 1.000 1.000 
Space group P212121 P212121 
Cell dimensions   
a, b, c (Å) 63.23   66.03  203.26 63.47   65.92  204.25 
α,β,γ (°) 90  90  90 90  90  90 
molecules per ASU 2 2 
Resolution (Å) 101.63-1.50 
(1.51-1.50) 
204.25-1.60 
(1.61-1.60) 
Rmerge 0.082(0.319) 0.097(0.411) 
I/σI 14.0(5.0) 13.3(4.9) 
Completeness 99.5% (96.6%) 99.7% (99.7%) 
Multiplicity 6.4(6.7) 6.4(6.5) 
No. observations 878235 (8862) 729227 (7586) 
No. unique reflections 136219 (1325) 113574 (1175) 
   
Refinement   
   Resolution (Å) 33.87-1.50 32.54-1.60 
   Rwork/Rfree 0.1680/0.1913 0.1791/0.2014 
   No. atoms 7317 6944 
   No. water 654 328 
   No. ligand molecule 2 2 
   No. PLP molecule 2 2 
   No. other molecule 0 0 
Ramachandran plot   
   Favored 97.4% 97.7% 
   Allowed 2.0% 1.7% 
   Disallowed 0.6% 0.6% 
R.m.s deviations from ideal geometry 
Bond lengths (Å) 0.007 0.007 
Bond angles (°) 1.24 1.21 
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Table 5.4 ITC data for H03 (A), H03-1 (B) and H03-2 (C). 
 
 N KD, nM ΔH, kcal 
mol-1 
ΔG, kcal 
mol-1 
-TΔS, kcal 
mol-1 
H03 0.998 654 -5.8 - 8.4 2.6 
H03-1 1.00 211 -7.71 - 9.07 1.36 
H03-2 1.00 103 -12.37 - 9.49 2.88 
 
 
H03-­‐1 H03-­‐2 H03 
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5.4 Discussion 
 
5.4.1. BioA co-crystallization with ligands  
All structures described herein involving higher-potency inhibitors of BioA were obtained 
from crystals derived from co-crystallization rather than soaking.  Soaking protocols 
successfully employed in the preparation of fragment-bound crystals are described in 
Chapter 3.  Both approaches were used to prepare crystals with more potent 
compounds, but co-crystallization produced better results. Diffraction data obtained from 
holo BioA crystals soaked with H02-H05 gave rise to no observable ligand electron 
density, and electron density quality for H01 was not as good when obtained using 
soaked crystals. The preparation of BioA crystals by co-crystallization is slightly slower 
than the preparation of holo BioA crystals; co-crystals appear in 72 hours and grow to 
their full size in 7 days while BioA holo crystals grow to their full size in 3 days. The 
quality of the crystals is improved when co-crystallized with the HTS compounds, so the 
investment of additional time and protein is justified.  
 
5.4.2. Conformation of the cyclopentanone in H03-1 
A cyclopentanone is fused on the benzene group in compound H03-1. A cyclopentanone 
is usually stable in an “envelope” or half-chair conformation. However, in the complex 
with bound H03-1, this 5-membered ring is in a planar conformation. We confirmed this 
planar conformation using the electron density generated from our X-ray data. We have 
modeled this cyclopentanone in the two different conformations to see which one best fit 
the electron density. When we model the density using an envelope shaped 
conformation of the cyclopentanone, we can see unmodeled density for the 5-membered 
ring (Figure 5.7A shown in green). When modeled as a planar 5-membered ring, the 
structure fits the density perfectly (Figure 5.7B). This cyclopentanone is capable of a 
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keto-enol tautomerization (Figure 5.7C). This tautomerization alters the functional group 
hydrogen bonding capability. The keto form can only be an acceptor, while the enol form 
can potentially be a donor or an acceptor. 
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Figure 5.7 Conformation of the cyclopentanone in H03-1. 
 
The H03-1 cyclopentanone is better fit into the planar conformation model. A) An 
envelope conformation modeled to fit the ligand density; B) A planar conformation 
modeled to fit the ligand density; C) Upper: inhibitor (H03.1) designed by merging H03 
with F9. Lower: the ketone-enol tautomerization of the cyclopentanone in H03-1. Since 
the cyclopentanone is in a planar conformation, its binding structure information can give 
us a clue of how H03.1 would bind. 
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5.4.3. Improved inhibitor binding affinity by optimization based on fragment merging  
H03-1 is a very nice example of fragment-based drug discovery, in which fragment 
information is used as one aspect of an overall lead discovery program. However, such 
opportunities are not always easy to find. More often it is hard to find common binding 
features of two hit molecules, also there are cases after merging the features, the 
designed compound does not bind in the predicted conformation. From our design 
experience, more iterations of modification with smaller modification in each step can 
increase the success rate in the optimization process. As we have obtained improved 
BioA inhibitors using fragment merging (H03-1 and H03-2), we can continue to merge 
features of H03-1 and H03-2 to aim for further increase in activity.   
 
5.5 Conclusion 
In this chapter, we described our biophysical and structural characterization of some 
BioA inhibitors from HTS. The DSF results showed that all of the HTS hits are stabilizing 
BioA protein in solution. Further validation using X-ray crystallography confirmed that 6 
out of the 8 HTS compounds bind in the BioA active site. We used our structure analysis 
and fragment merging strategy to propose optimized inhibitors for synthesis. Two 
analogs of HTS hit H03, one of them based on our design (H03-1), were synthesized by 
our collaborator Dr. Feng Liu. We characterized the optimized compounds using X-ray 
crystallography and ITC. The observed binding is very much as predicted based on 
modeling. We also observed increased binding affinity as determined by calorimetric 
measurements. 
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Chapter VI: Conclusion 
 
The fragment based inhibitor design project starts with a three-stage fragment 
screening. Initial DSF screening reduced our workload for structural characterization by 
identifying 21 initial hits from the 1000 compound library. From the complex structures 
from X-ray crystallography we obtained the most important information for further 
molecular design. ITC was then used to analyze the thermodynamics of compound 
binding. Data from ITC not only enable us to rank the hit compounds by binding affinity, 
but more importantly, it can be correlated with the structural information to understand 
how different interactions and different conformational changes affect the enthalpy and 
entropy of the target. 
  
Although strategies for FBDD are most commonly categorized into 3 classes (fragment 
extension, fragment linking and fragment merging), the use of the fragment information 
should never be limited to these classified methods. Creative and useful methods can be 
developed when two concepts are combined together. The fragment hits all bind in the 
same sub-site of BioA, which makes fragment linking very hard. Thus we focused on 
small modification and extension of the fragments in Chapter 4, and discovered a novel 
mechanism based inhibitor F10-1 and an analog of F5 with 2 fold increased binding 
affinity (F5-1). In chapter 5, we showed examples of merging fragments with HTS 
compounds to perform rational scaffold hopping. HTS analog H03-1 is very similar in 
structure to several of those we have designed via fragment merging, and our structural 
and biophysical characterization gives us confidence that our designed inhibitor H03.1 
will bind as predicted. 
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The completion of this thesis does not represent a completion of this project, but rather a 
beginning. Incremental modifications of known BioA inhibitors should continue in small 
steps, considering the flexibility of the BioA active site. Most of the compounds examined 
so far have been available from commercial sources, but structural data generated here 
establishes considerable opportunities for the design and synthesis of novel and specific 
BioA inhibitors with better therapeutic potential.
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